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Background Inorganic nitrite, a metabolite of endogenously produced nitric 
oxide (NO) from NO synthases, provides the largest endocrine source of 
directly bioavailable NO.  The conversion of nitrite to NO occurs mainly through 
enzymatic reduction, which is particularly favoured under hypoxia. Thus, current 
evidence shows that nitrite dilates small resistance arterioles where conditions 
of hypoxia predominate. Although organic nitrates/nitrites also mediate their 
principal effects via NO, they are not hypoxia dependent; hence, they 
selectively dilate muscular conduit arteries, lowering central blood pressures. 
Inorganic nitrite would be expected to lack such effects. 
Methods and Results The effects of local and systemic administration of 
sodium nitrite on the radial artery (RA) a muscular conduit artery, forearm 
resistance vessels (forearm blood flow) and systemic haemodynamics in 
healthy male volunteers (n=43) were examined. Intra-brachial sodium nitrite 
(8.7 μmol/min) increased RA diameter by 28.3% (95% CI 20.3 to 36.2). Nitrite 
(0.087-87 μmol/min) displayed similar selectivity as glyceryl trinitrate (0.003-1 
μg/min) for conduit arteries, compared to resistance arterioles. Nitrite dose-
dependently increased local cGMP production from the dose of 2.6 μmol/min, 
by 1.1 pmol/min/100ml tissue (95% CI 0.5 to 1.8). Vasodilatation of the RA by 
nitrite was enhanced by administration of acetazolamide (oral or i.a.) and oral 
raloxifene (P=0.0248, P<0.0001 and P=0.0006, respectively) but was inhibited 
under hypoxia (P<0.0001) and hyperoxia (P=0.0006) compared to normoxia. 
Systemic intravenous administration of sodium nitrite (8.7 μmol/ min) dilated the 
RA by 10.7% (95% CI 6.8 to 14.7) and reduced central systolic BP by 11.6 
  
3 
mmHg (95% CI of difference 2.4 to 20.7), augmentation index and pulse wave 
velocity, without changing peripheral BP.  
Conclusions Nitrite is a normoxia-dependent selective conduit artery dilator. 
The mechanism is via cGMP, and the effect is enhanced by acetazolamide and 
raloxifene. The selective central blood pressure-lowering effects of nitrite have 
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DBP –  Diastolic blood pressure  
DPI –   Diphenylene iodonium  
Drp1 –  Dynamin-related protein 1  
ECG –  Electrocardiogram  
ED –   Endothelial dysfunction 
EDRF –  Endothelium derived relaxing factor  
EDTA –  Ethylene diamine triacetic acid 
ELISA –  Enzyme-linked immunosorbent assay  
eNOS –  Endothelial nitric oxide synthase 
FAD –  Flavin adenine dinucleotide  
FAO –  Food and agriculture organization of the United Nations 
FBF –  Forearm blood flow 
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FMD –  Flow mediated dilatation  
GSNO –  S-nitrosoglutathione  
GTN –  glyceryl trinitrate 
GTP –  Guanosine triphosphate  
Hb –   Haemoglobin  
Hb-NO –  Nitrosylated Haemoglobin 
HO-1 –  Haem oxygenase-1  
HPLC –  High performance liquid chromatography 
HR –   Heart rate  
IH –   Intimal hyperplasia  
IL-1b –  Interleukin-1 beta 
IL6 –   Interleukin 6  
INFγ –  Interferon-γ  
iNOS –  Inducible nitric oxide synthase 
IPC –   Ischemic preconditioning 
IRI –   Ischemia reperfusion injury 
ISDN –  Isosorbide dinitrate 
ISIS-4 –  Fourth international study of infarct survival 
ISMN –  Isosorbide mononitrate 
LVDP –  Left ventricular developed pressure 
LVEF –  Left ventricular ejection fraction 
MAP –  Mean arterial pressure  
Mb –   Myoglobin 
MI –   Myocardial infarction 
MPTP –  Mitochondrial membrane permeability transition pore 
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NAD –  Nicotinamide adenine dinucleotide 
NADPH –  Nicotinamide adenine dinucleotide phosphate 
NFAT –  Nuclear factor of activated T cells 
Ngb –  Neuroglobin 
nNOS –  Neuronal nitric oxide synthase 
NO –   Nitric oxide  
NOA –  Nitric oxide analyser  
NOS –  Nitric oxide synthase 
NSB –  Non-specific binding 
PAD –  Peripheral artery disease 
PAP –  Pulmonary artery pressure 
PDE5 –   Phosphodiestersae type 5  
PEdiN –  Pentaerithrityl dinitrate 
PEEP –  Positive end expiratory pressure 
PEmonoN –  Pentaerithrityl mononitrate   
PETN –  Pentaerithrityl tetranitrate  
PEtriN _  Pentaerithrityl trinitrate  
PGC1α –  Proliferator-activated receptor-γ coactivator 1α  
PKA –  Protein kinase A  
PMT –  Photomultiplier tube 
pSBP –  Peripheral systolic blood pressure  
PWV –  Pulse wave velocity  
RA –   Radial artery  
ROS –  Reactive oxygen species  
SBP –  Systolic blood pressure  
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SD –   Standard deviation  
sGC –  Soluble guanylate cyclase 
SNO –  S-nitrosothiol  
SNO-Hb –  S-nitrosylated Haemoglobin 
SO –   Sulphite oxidase 
TMB –   3,3’,5’5’-tetramethylbenzidine  
TNFα –  Tumour necrosis factor-α 
US –   Ultrasound 
V-HEFT –  Vasodilator heart failure trial 
VOP –  Venous occlusion plethysmography 
WHO –  World health organization  
XDH –  Xanthine dehydrogenase  
XO –   Xanthine oxidase 
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1.1 Inorganic nitrite 
1.1.1 Overview  
In contrast to the structurally complex and chemically synthesised organic 
nitrates/nitrites, inorganic nitrite (NO2
-) is a simple naturally occurring anion. 
Under normal physiological conditions, the majority (~70%) of circulating and 
stored nitrite is derived from the oxidation of nitric oxide (NO), endogenously 
produced via the L-arginine NO synthase (NOS) pathway 1-3.  The remainder 
(~30%) is acquired through dietary intake, via the recently described Nitrate-
Nitrite-NO pathway 4.  While concentrations in the circulation are low under 
basal conditions (90-350 nM) 5-8, nitrite accumulates substantially in tissues (1-
20 μM) 9-11, with the highest concentrations in the liver, kidney, heart and 
topmost in the aorta 11,12.  
Although nitrite is freely available in the environment, it is only found in trace 
amounts compared to inorganic nitrate (NO3
-) 13.  Both are formed by the 
fixation of atmospheric nitrogen and oxygen, either directly through lightning, or 
indirectly through the actions of specialized bacteria; the latter being the more 
significant of the two processes.  These anions are normally bonded to metal 
cations (commonly Na+ or K+) and exist as hydrophilic salts that permeate into 
water and soil 14,15. Plants, especially green leafy vegetables and beetroot, take 
up nitrate avidly 4,13. In turn the ingestion of these nitrate rich plants by 
mammals provides a major source of nitrite through the entero-salivary circuit 4.  
Once ingested, nitrate is readily absorbed via the upper gastrointestinal tract 
avoiding first pass metabolism 7,16,17. Within a 24 hour period ~75% of the 
absorbed nitrate is excreted by the kidneys; of the remainder ~25% is taken up 
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by the salivary glands, with only trace amounts secreted via sweat glands 6,7. 
The nitrate rich saliva is then excreted into the oral cavity where bacteria found 
on the dorsal part of the tongue convert it to nitrite via nitrate reductases. A 
number of bacterial species contribute to this process to varying extents, the 
most notable of these being the Veillonella species, Actinomyces species, and 
Rothia species 18. Nitrite is swallowed, and absorbed via the upper 
gastrointestinal tract leading to a rise in circulating levels. However, a proportion 
of this nitrite is protonated under the acidic conditions normally found in the 
stomach, forming nitrous acid which in turn decomposes to NO and other 
derivatives (see Equations 1-4) 19,20. Although the entero-salivary circuit is the 
major pathway for nitrate reduction to nitrite in mammals, another possible 
mechanism described in a murine model, and in rodent and human liver 
homogenates, suggests direct reduction of nitrate to nitrite via the actions of 
hepatic xanthine oxidoreductase 21.    
1.1.2 Nitrite in tissue and circulation 
As recently as 2001, nitrite was viewed as biologically inactive, and its only 
utility was as a marker of endogenous NO production, thus reflecting NOS 
activity 5.  Furchgott demonstrated in 1953 that high concentrations of nitrite 
(100 and 1000 μM) relaxed strips of rabbit thoracic aorta 22.  Although lower 
concentrations were not tested, it was generally inferred that at physiological 
concentrations nitrite was biologically inactive. In 1994, Benjamin et al, and 
Lundberg et al, independently demonstrated for the first time that nitrite can be 
reduced to NO in a biological system - under the acidic conditions present in the 
human stomach 19,20. A year later, in 1995, Zweier et al, suggested that nitrite, 
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via a similar mechanism of direct reduction, may provide an alternative source 
of NO in the ischemic heart, where NOS plays a diminishing role 23. By looking 
at both NO metabolites (endogenous nitrate and nitrite) Cicinelli et al, 
suggested in 1999 that an arterial-to-venous (AV) gradient may exist 24. A year 
later Gladwin et al, specifically investigated endogenous nitrite, and 
convincingly demonstrated the existence of an AV gradient, suggesting that 
nitrite is reduced to NO across the vascular bed under normal physiology 25.  
However, others maintained the gradient in fact reflected differences in NOS 
activity and NO production in the arterial vs. venous system 26.    In 2001, Modin 
et al, found that nitrite in physiological concentrations was an effective 
vasodilator of rat aortic rings under conditions of low pH (6.6) and normoxia 
(6.5% CO2 and 93.5% O2). With this finding, an active biological role for nitrite in 
vascular tone was hypothesised 27. It was Cosby et al, who demonstrated in 
2003, that intra-brachial infusion of minimally supra-physiological concentrations 
of nitrite caused a significant increase in forearm blood flow 28. This discovery 
resulted in the acceptance of nitrite as a physiological source of biologically 
active NO, making nitrite the largest directly accessible storage pool for NO.  
Although nitrate is found in much higher concentrations in the circulation and 
tissues, nitrate requires a two-step reduction to NO, via nitrite.  In 2008, Maher 
et al, demonstrated significant enhancement of nitrite-induced vasodilatation 
under hypoxic conditions in humans, suggesting greater rates of reduction of 




1.1.3 Mechanisms of nitrite reduction to nitric oxide 
1.1.3.1 Acidic disproportionation  
It has long been established that eNOS plays an important role in myocardial 
NO production 30-32, with an estimated ~1000 pM/s of NO being produced under 
normal physiological conditions 33. Ischemia however markedly reduces eNOS 
activity and NO production 33,34. These same conditions of low oxygen tension 
and low pH significantly enhance nitrite reduction, releasing quantities of NO 
which far exceed those produced by eNOS under such conditions 35. It has 
been estimated that under ischemic conditions, NO production from nitrite (10 
μM) in the heart is ~560 pM/s 33.  
Under acidic conditions, nitrite exists in equilibrium with nitrous acid (Equation 
1). Both exist in equilibrium with other intermediates (Equations 2 & 3), including 
dinitrogen trioxide (N2O3), which breaks down to form nitrogen dioxide (NO2) 
and NO (Equation 4) 28,35,36.  
H+ + NO2
-  HNO2                     (1) 
HNO2  NOOH              (2) 
NOOH + NO2
-  N2O3 + OH
-                    (3) 
N2O3  NO2 + NO             (4) 
Thus simple nitrite disproportionation, which increases under acidic conditions, 




1.1.3.2 Enzyme facilitated reduction 
However, in tissues, the process of disproportionation accounts for only ~15-
20% of the total NO produced from nitrite 35; the remainder is derived from 
enzymatic nitrite reduction 33.  A host of proteins have now been shown to 
possess nitrite reductase activity; these include haem-associated globins, 
molybdenum metallo-enzymes, mitochondrial proteins, cytochrome P450 and 
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eNOS – endothelial cells, epithelial cells of 
respiratory and GI tract, hepatocytes and 
skeletal muscles 
nNOS – Neuronal cells, cardiomyocytes, 
vascular and smooth muscle cells, skeletal 
muscle 
iNOS – inducible in a host of cells which 
express eNOS and nNOS 
64,65
 
Table 1.1: List of enzymes implicated in the production of NO from nitrite. CSF – Cerebrospinal 
fluid, GI– gastrointestinal tract, XDH – Xanthine dehydrogenase, XO – Xanthine oxidase, CNS – 
central nervous system, CVS – cardiovascular system, CA – Carbonic anhydrase, eNOS – 
endothelial nitric oxide Synthase, nNOS – neuronal nitric oxide Synthase, iNOS – inducible 
nitric oxide synthase. 
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1.1.3.2.1 Haem-associated globins  
Haemoglobin (Hb), myoglobin (Mb), neuroglobin (Ngb) and cytoglobin (Cgb), 
belong to an extended family of haem-associated globin proteins, found in 
almost all living organisms. They have evolved from a single ancestral protein, 
and are mainly concerned with handling oxygen storage and delivery 37,42,66. 
While the haem portion, composed of an iron atom within a tetrapyrrole ring 42, 
provides the redox-capacity of the protein, it is the globin subunit that guards 
against rapid oxidation. This directs the redox potential which allows for the 
reversible binding of oxygen 67. In addition to this oxygen binding capacity, 
haem-associated globins manifest enzymatic activity, reacting with a range of 
compounds such as sulphides, peroxides, NO and its metabolites 42. However, 
this enzymatic activity is limited under normal physiological conditions 42.  
All the mammalian haem-associated globins have been shown to possess 
nitrite reductase activity in their deoxygenated state, in a well-characterized 
reaction (Equation 5) 68. 
Deoxy Fe(II) + NO2
- + H+  Fe(III) + NO + OH-         (5) 
 
However, the somewhat intriguing, parallel paradox is that haems, particularly 
Hb and Mb, are long-established avid scavengers of NO in their oxygenated 
state (see Equation 6). Thus there exists a delicate balance between nitrite 
reduction to NO and NO oxidation to nitrate in the presence of haem.  This led 
to the proposal of a responsive oxygen-sensing role of Hb through nitrite and 
NO, which serves as an important modulator of vasodilatation 28.   
  29 
1.1.3.2.1.1 Haemoglobin 
Haemoglobin is a complex protein composed of four globin protein subunits, 
each linked to a haem molecule. The four subunits are composed of two α– and 
two β– globin proteins, which share only 50% of their polypeptide sequence 37.  
Normal blood Hb concentrations in humans are 12-15 mmol/L (~150 g/L), 
located mostly in erythrocytes 37,69 where levels of nitrite exceed those of 
plasma (~290 nM and ~120 nM respectively) 70. 
Oxygenated Hb (O2-Hb
Fe(II)) acts as a nitrite oxidase producing nitrate and 
metHb (HbFe(III)) (Equation 6) 26, a reaction described almost 140 years ago by 
Arthur Gamgee 68,71. 
4 O2-Hb
Fe(II)  + 4NO2
- + 4H+  4 HbFe(III) + O2 + 4NO3
- + 2H2O                 (6) 
An interaction between deoxygenated Hb (deoxyHbFe(II)) and nitrite was 
recorded by John Haldane in  1901 72.  It was Doyle et al, who in 1981, further 
elucidated the role of deoxyHb as a nitrite reductase leading to the production of 
NO and metHb via a nitrosylhemoglobin intermediate  (Equation 7) 73.   
deoxyHbFe(II)+NO2
-+H+  HONO+ Hb  Hb-NO+ OH- HbFe(III) + NO+ OH-   (7) 
The potential biological significance of nitrite as a source of NO under hypoxic 
conditions was then highlighted by Reutov et al, in 1993 74.  The oxygen-
dependence of this reaction, was demonstrated by Cosby et al, in 2003, where 
the use of deoxygenated erythrocytes resulted in significantly more NO being 
released 28.  However, rather than occurring at complete deoxygenation, peak 
NO production was found to occur at ~50% oxygen saturation of both free-, and 
erythrocyte-bound Hb 75,76. This may be explained by a differential rate of 
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reaction between Hb in the “R” (relaxed, oxygenated) state, which reacts with 
nitrite ~10-fold faster than Hb in the “T” (tense, deoxygenated) state 77,78. The 
nitrite reductase capacity of Hb occurs most rapidly when it is partially 
oxygenated and adopts the R3 state, with three of the four haem moieties 
bound to oxygen 77.  
In support of nitrite’s biological significance as a source of NO during hypoxia, 
the addition of nitrite in physiologically relevant doses (10 nM to 10 μM) to rabbit 
or rat aortic rings in the presence of erythrocytes at high oxygen tensions 
resulted in only a small vasodilatory effect when compared to controls 76. 
However, nitrite’s dilatory effect became considerably more potent as the 
oxygen tension was reduced, so that concentrations of nitrite as low as 200 nM 
resulted in a significant dilatation 76. And so it has been suggested that as 
erythrocytes traverse the vasculature from the arterial to the venous side, the 
fraction of deoxyHb increases and on reaching the arteriolar bed, where the 
partial pressure of oxygen approaches the p50 of Hb, production of NO from 
nitrite is optimally supported 28,79.   
A limitation of this elegant mechanism of nitrite reduction is the explanation of 
how NO escapes scavenging by oxyHb, within the confines of the erythrocyte, 
to exert its effects on the vasculature.  Haemoglobin is such an avid scavenger 
of free NO, that free Hb in low concentrations (1000-fold less than in 
erythrocytes) leads to marked depletion of circulating NO, elevating basal 
vascular tone, resulting in hypertension in humans and animal models alike 
69,80,81.  The affinity of free Hb for free NO, is thought to be a property of both 
oxyHb and deoxyHb alike. OxyHb reacts with free NO, yielding metHb and 
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nitrate (Equation 8). Whereas deoxyHb reacts with free NO producing 
nitrosylated-Hb (Hb-NO) (Equation 9) 79,82.  
O2-Hb
Fe(II)+ NO  HbFe(III) + NO3
-              (8) 
deoxy-HbFe(II) + NO  Hb-NO              (9) 
Several hypotheses attempt to tackle the conundrum of how NO escapes 
scavenging by cell bound Hb. The first of these suggests that NO is produced in 
specific compartments of the erythrocyte then actively released into the 
circulation 28. Another hypothesis, proposes the formation of an s-nitrosothiol-
Hb (SNO-Hb) intermediate, which releases NO during transit from the oxygen-
rich arterial system, to the oxygen-deplete venous system 26,83. However, 
although levels of SNO-Hb have been detected in animal models, their 
presence in humans at physiologically relevant concentrations has not been 
confirmed 84,85. A further hypothesis, suggests that the reaction of nitrite and 
deoxyHb leads to the formation of N2O3, or other non-specified intermediates, 
which can more readily escape the erythrocyte, and once outside, dissociate 
releasing NO 28,86,87. Thus, although the reductase capacity of Hb has been 
demonstrated, its relative biological contribution remains to be established.   
All the reactions of nitrite and nitrate with deoxy-, oxy- and met- haems are 
summarised in Table 1.2. 
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1.1.3.2.1.2 Myoglobin 
Originally described as “muscle haemoglobin” 88, Mb comprises a single unit 
which shares a near-identical 3D structure with Hb’s α- and β-subunits 37. In 
mammalian models, Mb predominates in skeletal, cardiac and smooth muscle 
38. However, Mb has also been shown to be present in the brain, liver and 
kidneys of hypoxia tolerant carp 39. Concentrations of Mb are ~0.33 mmol/L in 
human myocardium, ~0.5 mmol/L in the skeletal muscles of terrestrial 
mammals, but are ~10-fold greater (~3.8 mmol/L) in marine mammals 89.  Given 
the abundance of this haem-associated globin in the skeletal, and cardiac 
muscle of diving marine mammals and animals living in high altitudes 90, Mb’s 
sole role was considered to be oxygen storage and handling in mitochondria-
rich muscle cells.  By enhancing oxygen diffusion, especially under acidic 
conditions 42, Mb aids endurance muscle activity during periods of hypoxia and 
anaerobic exercise 91.  And so it came as a surprise when Mb-knockout mice 
displayed no adverse effects, and no reduction in their endurance capacity or 
response to hypoxia 90.  
In view of these findings, one may well have questioned Mb’s actual function. 
However, there is now evidence of an important reaction between deoxyMb and 
nitrite 92.  For example, in an ex-vivo model, deoxyMb was shown to be an 
effective nitrite reductase 40,75,77, catalysing the production of NO ~36-fold faster 
than deoxyHb 40.  The dependence of nitrite reduction on Mb, was further 
confirmed in-vivo, in a study utilising a mouse model deficient in the protein 88. 
Fully deoxygenated Mb produces NO at a rate of ~1.5 pmol/L/s from nitrite (10 
μmol/L) 88, resulting in the formation of metMb. That NO is readily detectable 
suggests that it evades scavenging by metMb, which has a low affinity for NO 
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88. Thus under hypoxic conditions, deoxyMb acts as an NO generator 40,88, with 
an important role in hypoxia-mediated vasodilatation 12,93. However, under 
aerobic conditions, oxyMb rapidly scavenges NO, producing metMb and nitrate 
42,82,88,94, displaying an oxygen-sensing role similar to that of Hb (See table 1.2.).  
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1.1.3.2.1.3 Neuroglobin and Cytoglobin 
Neuroglobin and cytoglobin are hexa-coordinated haem-associated globins, 
which share less than 25% of their structure with Mb and Hb. They are found in 
much lower concentrations (~0.2 μM) in vertebrates; but their expression is 
significantly up-regulated in hypoxia 45,95,96. With Cgb this up-regulation is by a 
factor of ~1.8 to 2.5 depending on the tissue and the duration of hypoxia 96. 
Neuroglobin was originally isolated from neuronal cells in the brain in 2000 41, 
but is also expressed in endocrine cells 41-43. Cytoglobin is found in the 
cytoplasm of all tissues and organs of vertebrates, with greatest expression in 
the brain, eyes, liver, heart and skeletal muscle 43,46.   
As with Hb and Mb, the deoxygenated forms of Ngb and Cgb reduce nitrite to 
NO 44,97. In addition, Cgb’s action is potentiated under conditions of low pH: 
rates of nitrite reduction double when the pH falls from 7 to 6, increasing 15-fold 
at pH 5.5 97. Transformation to a penta-coordinated structure is required for 
nitrite reductase activity. In Ngb, this is achieved by the oxidation of two of the 
globin’s surface cysteine residues (cysteine-46 and -55) forming a disulfide 
bridge 44,97. This diminishes the globins’ affinity for the haem-iron, resulting in 
the transformation from a hexa- to a penta-coordinated structure, with greater 
affinity for nitrite 98. The resulting mechanism of nitrite reduction is similar to that 
of Hb and Mb (see Table 1.2).   
Neuroglobin has been shown to have a protective effect limiting neuronal cell 
death 44, suggesting a role similar to that of Mb in muscle cells. However, the 
low abundance of Ngb and Cgb questions their significance as nitrite 
reductases under physiological conditions 99,100.   
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Table 1.3 compares the nitrite reductase activity of all the haem-containing 





DeoxyFe(II) MetFe(III) + NO  Fe(II)-NO           (iron-nitrosylated Hb) 
OxyFe(II) MetFe(III) + NO3
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Protein Haemoglobin Myoglobin Neuroglobin Cytoglobin 
 
Transition required 




between the R 
and T state 
Transition 
















tension – p50 
20 -26 mmHg 
2.2-2.4 
mmHg 




pH 7.4 7.4 7.4 7.0 
Protein 50 μM 25 μM 10 μM 10 μM 
Nitrite 2.5 mM 20 μM 10 mM 2 mM 
k 
(M-1s-1)  
~4.4 ~12.4 ~0.26 ~0.14 
Refs  42,75,101 40,42,101 42,44,101 96,97 
Table 1.3: Comparison of the nitrite reductase activities of haem-containing globins 
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1.1.3.2.2 Mitochondrial enzymes   
The capacity of mitochondria to reduce nitrite under anoxia was recognised by 
Taylor as early as 1965 102. Although the observation pertained to nitrite’s action 
in preserving meats, this has also been demonstrated in a physiological setting, 
in a process which involves the terminal components of the oxidative chain: 
complex III, Cytochrome C (CytC) and complex IV 47,50,101,103.  A role for 
complex III was suggested in an early paper through the demonstration of 
inhibition of mitochondrial nitrite reduction, under anaerobic conditions, by 
myxothiazol (a competitive inhibitor of ubiquinol and the activity of complex III) 
47.   
Complex IV, also known as Cytochrome C oxidase (CcOx), the terminal part of 
the mitochondrial chain, reduces 95% of inspired oxygen 49. Nitrite, is also 
reduced by CcOx; however, extremely low concentrations of oxygen (~2%) are 
required 50, as oxygen inhibits nitrite reduction in a competitive process.  
Furthermore, different CcOx isoforms exist, which possess a range of nitrite 
reductase activities, with the relative expression of each isoform being 
modulated by oxygen 104. However, the physiological implications of these 
finding are uncertain given the requirement for such low oxygen concentrations. 
Cytochrome C is an inter-mitochondrial membrane haemprotein, which 
transfers electrons from complex III to CcOx 48. Thus, CcOx is dependent on 
CytC to reduce nitrite 50. However, CytC also reduces nitrite independently of 
CcOx 48. This activity is dependent on its adoption of a penta-coordinated 
geometry in a manner similar to that required by Ngb and Cygb 48. However, 
CytC is unable to shuttle electrons in its penta-coordinated form, bringing into 
question the physiological relevance of this reaction.   
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1.1.3.2.3 Molybdenum metallo-enzymes  
The family of molybdenum-containing enzymes includes xanthine 
oxidoreductase, aldehyde oxidase, sulphite oxidase and bacterial nitrate/nitrite 
reductases 105,106. These enzymes support the catalysis of a wide range of 
redox/ hydroxylation reactions 105,106 dependent on molybdenum (Mo) which can 
exist in a range of oxidation states: Mo(IV), Mo(V) and Mo(VI) 106.  
1.1.3.2.3.1 Xanthine oxidoreductase 
Xanthine oxidoreductase (XOR) refers to two inter-convertible enzymes found in 
mammalian cells: xanthine oxidase (XO) and xanthine dehydrogenase (XDH) 51. 
Xanthine oxidoreductase exists as homodimer and plays a key role in purine 
metabolism by catalysing the oxidation of hypoxanthine to xanthine, which in 
turn is further oxidised to uric acid 51,52. Thus purine oxidation donates electrons 
to the Mo site, with reduction of Mo(VI) to Mo(IV) 106. The Mo site may be 
similarly reduced following oxidation of NADH at the flavin adenine dinucleotide 
(FAD) site, which results in the reduction of FAD to FADH2, from where 
electrons may be transferred to the Mo site 106. The reduced FAD site (FADH2) 
of XOR also supports the reduction of oxygen to reactive oxygen species (ROS) 
including superoxide and H2O2 (see Table 1.4). Xanthine dehydrogenase is the 
predominant intracellular isoform, whereas XO is mainly located on the 
extracellular membrane 107,108. Indeed, XOR is present almost exclusively as 
XO in plasma, due to the action of serine proteases on XDH. Hypoxia induces 
the up-regulation of XOR expression, activity, and its release into the 
circulation, from endothelial cells 109.  Fasting and ischemia irreversibly convert 
XDH to XO, through the oxidation of a critical cysteine, and proteolysis 107,110.  
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Xanthine oxidoreductase has been shown to reduce nitrite to NO 33,51,106,111.  In 
rat and human heart tissue, the addition of the molybdenum-site XO-inhibitor 
allopurinol attenuates NO production from nitrite by ~50%, in a pH-dependent 
manner 112. The nitrite reductase activity of XOR is attributed to the reduced 
Mo(IV) site (resulting from purine or NADH oxidation as described above) which 
donates electrons to nitrite 51,111 with concomitant oxidation to Mo(V) 106.  
However, reduction of oxygen at the FAD site creates competition with nitrite for 
electrons across XOR, inhibiting nitrite reduction with the molybdenum 
substrate, xanthine 113. Therefore, conditions of low oxygen tension favour 
XOR-mediated nitrite reduction, which is abolished at normal to high oxygen 
tension 51,111. However, in the presence of NADH, which competes with oxygen 
at the FAD site, nitrite reduction is maintained at ~70% of anaerobic levels 113, 
thus providing a mechanism of XOR-mediated normoxic nitrite reduction. Also, 
blockade of the FAD site with diphenylene iodonium (DPI) in the presence of 
oxygen enhances nitrite reduction to NO in rat aorta 114. In addition to the heart, 
functional XOR has been demonstrated on the surface of erythrocytes 115. 
Erythrocytic XOR may thus provide an additional pathway for nitrite reduction, 
which avoids scavenging by oxyHb. Indeed, this appears to have a role in 
hypertension, where erythrocytic XOR is up-regulated with greater nitrite 
reductase activity 116.  
Relative Activities XO XDH Ref 
Reduction of O2 to O2
- 100% 
25% for Rate 
But amount >100% 
117 
Reduction of NAD+ to 
NADH 
0% 100% 118 
Oxidation of NADH to 
NAD+ 
50% 100% 119 
Table 1.4: The relative activities of XO compared to XDH. The relative activities relate to the 
redox functions as stated for each substrate. 
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1.1.3.2.3.2 Aldehyde oxidase  
Aldehyde oxidase (AO), another molybdenum-containing enzyme, is involved in 
the oxidation of aldehydes, and hydroxylation of heterocyclic compounds 54.  
Aldehyde oxidase is an intracellular cytosolic enzyme, found in multiple organ 
systems, including the cardiovascular system, the central nervous system, the 
respiratory tract and the GI tract, with the highest expression and activity in the 
liver 54,55.  While mammals possess multiple isoforms of the enzyme, humans 
possess only one 54.  Sharing up to 86% of its structure with XOR, AO also 
reduces oxygen, generating ROS 55. However, it is unable to function as a 
dehydrogenase 33,110, and is not to be confused with the aldehyde 
dehydrogenases.  Similar to XOR, AO functions as a nitrite reductase, a 
process enhanced under acidosis and hypoxia 33. This was demonstrated by 
inhibition of NO production from nitrite by ~40%, in the liver with raloxifene 33.  
1.1.3.2.3.3 Sulphite oxidase 
Sulphite oxidase (SO) is also a molybdenum-containing enzyme, involved in 
sulphur amino acid degradation 120, catalysing the oxidation of sulphite (SO3
2-) 
to sulphate (SO4
2-) 121. Expressed in various tissues 57,the structure of human 
SO is different from XOR and AO, resembling that of plant nitrate reductases 
111, but possesses nitrite reductase activity 56.    
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1.1.3.2.4 Carbonic anhydrase  
Carbonic anhydrases are a class of metallo-enzymes, where the zinc ion plays 
a fundamental role, catalysing the hydration of carbon dioxide, yielding 
bicarbonate and a proton (Equation 10) 62,122,123. 
H2O + CO2  H2CO3  HCO3
- + H+                                                        (10) 
This hydration reaction takes place in all living organisms and is essential in 
many physiological processes, including respiration, CO2 transport, pH 
regulation, excretion, secretion and metabolic synthesis 62,124.  The key role of 
CA is the removal of CO2 from respiring tissues and buffering pH transients 
occurring with metabolic activity 125. 
Sixteen isoforms have been identified in vertebrates, fifteen of which have been 
isolated in man 122,126, located in the cell membrane, the cytosol and the 
mitochondria 62.  The commonest and most active isoenzyme in humans is CAII 
62,122,127, which is also the most abundant isoform in erythrocytes.  Indeed, CAII 
possesses one of the greatest rates of enzyme catalysis known 62,122,127. This 
supports a rapid local decrease in the capillary pH of active tissues, which in 
turn facilitates the release and delivery of oxygen from Hb (via the Bohr effect) 
128.  Given the similarities between NO2
- and HCO3
-, it has been hypothesized 
that CA may play a key role in nitrite metabolism 63. This hypothesis is 
supported by the observations that nitrite can inhibit CA by binding to the HCO3
- 
active site 129, and that CA acts on nitrite to release NO under conditions of low 
pH and normal oxygen tension 63. Surprisingly, inhibition of CA with dorzolamide 
or acetazolamide potentiates total NO release ~6-fold at pH 7.2, and ~2 fold at 
pH 5.9; however, the rate of production was unaffected. The zinc active site 
  41 
cannot participate in redox reactions to support nitrite reduction, but instead 
behaves as a nitrous anhydrase 63, catalysing the following reaction 
(Equation11): 
2NO2
- + 2H+  2HNO2  H2O + N2O3
-                              (11)                                                                                      
N2O3 then rapidly breaks down to form NO2 and NO (see Equation 4).  
Alternatively, the reaction may be supported by stepwise nitrosation in the 
presence of thiols (e.g. glutathione), with the formation of zinc thiolate and 
nitrous acid (HNO2); the latter further reacting with thiols to give a nitrosothiol 
130.  
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1.1.3.2.5 Nitric oxide synthase 
The NOS family of enzymes comprises three isoforms: neuronal NOS (nNOS / 
NOS1), inducible NOS (iNOS / NOS2) and endothelial NOS (eNOS / NOS3), 
with ~50% variation in protein structure between them 64,131. Through an 
oxygen-dependent reaction, NOS oxidises the guanidino nitrogen atoms of L-
arginine, forming NO and L-citrulline 131. In anoxia, when this reaction is 
impaired, it is now appreciated that eNOS can use nitrite as a substrate, 
restoring NO production to baseline levels 65,132. In elegant experiments, the 
nitrite reductase activity was located to the oxygenase domain of eNOS 65. The 
biological relevance of nitrite’s reduction by eNOS has been shown with human 
erythrocytes, whereby inhibition with L-NAME attenuated the production of NO 
from nitrite 115.   
1.1.3.2.6 Cytochrome P450 
Cytochrome P450 (CYP450) is a ubiquitous family of enzymes, belonging to the 
monooxygenase superfamily 58,59.  They are haem-containing proteins, mainly 
functioning as catalysts in the oxidation of organic compounds (RH) (Equation 
12) 60,133.  
O2 + RH + NAPDH + H
+  ROH + H2O + NADP
+            (12) 
Feelisch et al, found that the inhibition of microsomal CYP450 1A1, with 
ethoxyresorufin, attenuated the nitrite reductase activity of rat liver 
homogenates by ~40%, under hypoxic conditions 61. Curtis et al, also 
demonstrated a role for hepatic CYP450 in nitrite reduction, however no effect 
in heart, lung or brain was found 134.  
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1.1.4. Nitrite and cardiovascular protection  
The decline in circulating NO has been implicated in a number of cardiovascular 
disease processes 135,136. In humans, the number of cardiovascular risk factors 
is inversely correlated with plasma nitrite concentrations 8.  The restoration of 
NO levels, through exogenous nitrite, has a positive impact on a number of 
mammalian models of cardiovascular disease 137-143.  A summary of a selection 
of nitrite studies in cardiovascular protection is presented in Tables 1.5 and 1.6, 
and detailed descriptions in sections 1.1.4.1-1.1.4.6. 
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Table 1.5: Summary of studies into nitrite’s effects on cardiovascular disease models in 
humans: MI – Myocardial infarction, LVEF – Left ventricular ejection fraction. FMD – Flow 
mediated dilatation.   
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Table 1.6: Summary of studies into nitrite’s effects on cardiovascular disease in animal models: 
MI – Myocardial infarction, ED – Endothelial dysfunction, CPR – Cardiopulmonary resuscitation, 
CFR – coronary flow rate, LVDP – Left ventricular developed pressure, LVEF – Left ventricular 
ejection fraction, FMD – Flow mediated dilatation.  
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1.1.4.1 Endothelial dysfunction 
Hypercholesterolemia 154 and advancing age 155 have a clear association with 
the development of cardiovascular disease (CVD). This augmented risk is 
thought to be related to their induction of endothelial dysfunction, through a 
reduction in NO bioavailability, either as a result of reduced NO production, or 
increased NO consumption - mainly by ROS.  
Endothelial dysfunction, caused by hypercholesterolemia, leads to a 
proinflammatory phenotype in the microcirculation 156,157. Stokes et al, 
demonstrated that the supplementation of dietary nitrite in hypercholesterolemic 
mice prevented elevated C-reactive protein (CRP), micro-vascular inflammation, 
and endothelial dysfunction 158. Notably, nitrite had no effect on serum 
cholesterol levels (although triglyceride levels were reduced) suggesting a direct 
anti-inflammatory effect. 
Endothelial dysfunction, associated with old age, affects the arterial system 
leading to stiffening of the large elastic arteries 155. Sindler et al, found that older 
mice had ~45% lower levels of circulating and tissue nitrite 141. Supplementation 
with nitrite restored nitrite levels to those found in younger mice, and 
significantly reduced age related oxidative stress, endothelial dysfunction and 
arterial stiffening 141.  This mechanism was proposed to be via nitrite’s inhibition 
of elevated expression of NADPH oxidase (an important source of ROS) and 
cytokines (IL-1b, IL6, INFγ and TNFα).   
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1.1.4.2 Hypertension 
Nitrite, via reduction to NO (which has been proposed to be mediated by 
deoxyHb) vasodilates resistance arterioles, reducing mean blood pressure in 
healthy volunteers 28. Therefore nitrite has the potential to control hypertension, 
an important risk factor for CVD 154.  Indeed, nitrite administration to 
hypertensive rats reduces blood pressure 116,159-161, via reduction to NO by 
erythrocytic XOR 116, and down-regulation of vascular NADPH oxidase 161. 
Several studies show that supplementation with nitrate, as a source of nitrite 
(via the entero-salivary circulation), reduces BP in healthy volunteers 146,162-167 
and hypertensives 116.  In hypertensives, erythrocytic XOR expression is double 
that of normotensives, and this is associated with XOR-dependent nitrite 
reductase activity at pH 7.4 116, which was not seen in normotensives 115. It is 
therefore likely that this contributed to the substantial BP lowering effect when 
nitrate (~3.5 mmol) was given to grade 1 drug naive hypertensive patients 116.   
In a rat model of hypertension, the BP lowering effects of nitrite were abolished 
by the XOR inhibitor allopurinol further suggesting a key role for the enzyme in 
nitrite reduction to NO in vascular tissue 116. In addition, recent evidence 
suggests that nitrate derived from NOS under ‘basal’ (i.e. non-nitrate-
supplemented) conditions, also reduces blood pressure, as demonstrated by a 
consistent ~3 mmHg increase in systolic BP during a 7-day period of sustained 
antibacterial mouthwash use 168. This was associated with a ~25% decrease in 
circulating nitrite levels. Both effects were rapidly reversed on cessation of the 
mouthwash.   
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1.1.4.3 Intimal hyperplasia  
Vascular damage usually leads to an appropriate healing response. However, 
dysfunctional endothelial cells can cause an exaggerated healing response, 
leading to inappropriate remodelling and intimal hyperplasia (IH). This in turn 
leads to the development of plaques and flow-limiting disease 169,170. 
Furthermore, there is evidence that this inappropriate healing response is 
precipitated by attenuated NO availability 8,171,172.  
In a murine model of vascular injury, restricting nitrate/nitrite intake intensified 
the damage. By contrast, supplementation with nitrite protected injured 
vasculature from an inappropriate healing response, and resulted in the 
regression of IH 142. Although vascular injury was associated with amplified 
expression of XOR, the chronic inhibition of XOR worsened the vascular injury 
142. Furthermore, the protective effects of nitrite supplementation were lost, 
when nitrite was given in conjunction with the Mo-site XOR inhibitors, allopurinol 
and tungsten 142.  
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1.1.4.4 Peripheral artery disease  
Peripheral artery disease (PAD) results from atheroma in the arterial system, 
leading to interruption of blood flow to the extremities. Using a murine model, 
Kevil’s group demonstrated that intra-peritoneal (i.p.) nitrite administration 
during acute femoral artery ligation, had multiple beneficial effects, promoting 
endothelial cell proliferation, encouraging angiogenesis and arteriogenesis, 
enhancing vascular density, and re-establishing vascular flow into the ischemic 
limb 138. Many of the effects were evident within 3 days following ligation. These 
effects were abrogated by the NO scavenger carboxy 2-phenyl-4,4,5,5,-
tetramethylimidazoline-1-oxyl-3-oxide (C-PTIO). No nitrite-induced changes 
occurred in the non-ischemic limb 138.  Using the same model in hypertensive 
mice, the group demonstrated that oral supplementation with nitrite in the 
drinking water for 2 weeks following ligation, also resulted in total restoration of 
blood flow in the ischemic limb, associated with a rise in cGMP levels 148. These 
effects were prevented by XOR inhibition with allopurinol, suggesting a key role 
for nitrite-derived NO. In addition to producing similar beneficial effects in 
diabetic mice, post-ligation nitrite supplementation was also found to prevent 
tissue necrosis 149.  In humans with PAD, dietary nitrate supplementation (as a 
source of circulating nitrite) improved exercise time and time to exhaustion by 
~18% and 17% respectively 173.    
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1.1.4.5 Myocardial infarction  
Myocardial infarction is a result of coronary occlusion interrupting blood flow, 
causing myocardial cell necrosis through ischemia.  Ischemia leads to acidosis 
and ion imbalance within the cell.  While reestablishment of flow is necessary to 
reverse this process and salvage tissue, the reintroduction of oxygen 
consequent to reperfusion causes increased production and release of ROS, 
which leads to inflammation and accelerated cell death 174,175. The majority of 
experimental studies have demonstrated an important cardio-protective role for 
NO in ischemia reperfusion injury (IRI) 32,176.  Despite inorganic nitrite acting as 
a source of NO under ischemia and acidosis, nitrite was originally thought to be 
detrimental in IRI 23. However, in 2004 a protective effect in IRI was 
demonstrated in the heart by Webb et al, whereby nitrite (10 μM and 100 μM) 
attenuated infarct size by ~63% in an ex-vivo model of IRI, in the Langendorff 
rat heart 112. These protective effects were abolished by the NO scavenger C-
PTIO, demonstrating the requirement for nitrite reduction to NO. Since then, 
nitrite has been shown to have protective effects in the setting of myocardial 
infarction 137,139,152 as well as other organs subjected to an ischemic insult and 
reperfusion injury 137,177,178.  For example, Duranski et al, showed that the in-
vivo administration of intra-ventricular nitrite in mice, prior to reperfusion, 
resulted in a ~67% reduction in infarct size 137. This protective effect was also 
abolished with the NO scavenger C-PTIO, but was unaffected in eNOS 
knockout mice. This supports a role for nitrite-derived NO, as opposed to 
eNOS-derived NO.   
Shiva et al, showed that the administration of nitrite to mice, 24 hours before an 
ischemic insult, either via the i.p. or oral route (via needle gavage), attenuated 
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infarct size ~33.9% and ~52.7% respectively.  In addition, i.p. administration 
immediately before reperfusion reduced infarct size ~66% 151. Also in a murine 
model, Bryan et al, demonstrated a protective effect of 7 days oral 
supplementation with nitrite (50 mg/L in the drinking water), reducing infarct size 
~48% 150. Nitrite supplementation was associated with increased tissue stores 
of nitrite and SNOs – suggesting a protective mechanism via s-nitrosylation, in 
addition to that conferred by nitrite-derived NO 150. Importantly, dietary depletion 
of nitrate and nitrite had the opposite effects, increasing infarct size ~59% when 
compared to controls.  Gonzalez et al, simulated a myocardial infarction with 
revascularization therapy in a canine model, whereby nitrite was given 
intravenously either during the last 60 min or last 5 min of a 2 hour ischemic 
insult, reducing infarct size by ~67% and ~48.5% respectively 139.  
A role for XOR-mediated nitrite reduction was demonstrated by Webb et al, via 
inhibition of NO production using allopurinol and (-)BOF-4272, in homogenised 
rat and human myocardium, the latter collected from patients undergoing mitral 
valve replacement surgery 112.  Baker et al, confirmed the functional significance 
of XOR in the rat Langendorff IRI model, whereby oxypurinol blocked the 
protective effect of nitrite, and also showed important roles for NADPH oxidase, 
and sarcolemmal and mitochondrial ATP-sensitive potassium (KATP) channels in 
nitrite-mediated cardioprotection 153. Several studies provide evidence for Mb. 
For example, Rassaf et al, highlighted a functional role for nitrite reduction by 
deoxyMb, diminishing myocardial oxygen consumption and cardiac contractility 
in the Langendorff rat heart 88.  Moreover, Hendgen-Cotta et al, demonstrated 
that the administration of intra-ventricular nitrite prior to reperfusion attenuated 
infarct size by ~61%, an effect that was abolished in Mb-deficient mice 152. 
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Nicholson et al, recently reported surprising findings, whereby 4-weeks 
voluntary exercise in mice down-regulated myocardial Mb (via inhibition of 
calcineurin and NFAT signalling) attenuating myocardial nitrite reductase 
activity, and the beneficial effect of nitrite supplementation on myocardial IRI 179.  
Overall, it is likely that myocardial nitrite reduction proceeds with variable 
relative contributions from XOR and Mb, depending on the conditions and the 
species.  
While these studies were conducted in animal models, there is some evidence 
that this may translate to humans. For example, in an IRI model in the forearm 
of healthy volunteers, supplementation with dietary nitrate, as a source of nitrite, 
significantly attenuated IRI-induced endothelial dysfunction 146,165. Using a 
similar IRI model in healthy volunteers, Ingram et al, demonstrated comparable 
protection when intravenous nitrite was administered prior to, but not during the 
ischemic event 145. In patients with stable, but inducible myocardial ischemia, 
the intravenous administration of nitrite (1.5 μmol/min for 20 min) during a 
dobutamine stress echocardiographic study, resulted in a significant 
improvement in myocardial function in the ischemic territories, with no effect in 
the normally perfused areas 145. Though, in a recently reported trial, which 
attempted to replicate the design of the Gonzalez et al study, administering 70 
μmol of sodium nitrite to patients presenting with an acute ST elevation MI (as 
an i.v. infusion over 5 min prior to revascularization therapy) was found to be 
ineffective in mitigating the deleterious effects of IRI 144. This may in part be 
related to the dose of nitrite used which resulted in only a small rise in 
circulating nitrite concentration to 1.4 μmol/L (in the Gonzalez et al study the 
rise in circulating nitrite was ~5 μmol/L). The results of a further trial in which 
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nitrite was administered as an intracoronary bolus prior to reperfusion are still 
awaited 180.  
1.1.4.6 Cardiac arrest 
In a murine model of cardiac arrest, plasma heart and brain nitrite levels were 
found to be significantly depleted post-arrest 140. Treatment with nitrite peri-
arrest, partially restored these levels, improved cardiac function, reduced the 
incidence of arrhythmias and hypotension, and significantly enhanced left 
ventricular and right ventricular ejection fractions post-arrest 140. This in turn 
translated into a significantly higher survival rate in the nitrite-treated group 
compared to the placebo arm. A study looking at the same model in humans is 
underway 181.   
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1.1.5 Nitrite, Mitochondria and cardiovascular 
protection  
It is now clear that nitrite mitigates the deleterious effects of several 
cardiovascular pathological processes. The most widely investigated of which is 
IRI, where nitrite has been shown to be beneficial in a number of mammalian 
models, over a wide dose range and a broad temporal window.  Furthermore, 
the conversion of nitrite to NO is required to achieve most, but not all of its 
cytoprotective effects 112,137,143,151.  
While mitochondrial proteins act as nitrite reductases (as discussed in section 
1.1.3.2.2), nitrite also modulates mitochondrial function 40,151 structure 143 and 
density 182.  Also, tissues with higher mitochondrial oxygen consumption 
demonstrate greater nitrite reductase activity, suggesting a further link 61. 
Besides ATP generation, normal mitochondrial function includes redox 
signalling 183 and regulation of cell apoptosis 184.  However, these functions are 
also implicated in the progression of injury during ischemia and reperfusion 185. 
During ischemia, mitochondria shift from fatty acid to glucose metabolism, a 
less efficient source of energy and ATP generation 186. This anaerobic 
glycolysis results in decreased intracellular pH, mediated through the 
accumulation of H+, NADH and lactic acid 187-189. The continuation of these 
disturbances through persistent hypoxia leads to the cessation of ATP 
production, depletion of high-energy phosphate stores and cell death. With 
oxygen influx on reperfusion, mitochondria revert to oxidative metabolism of 
fatty acids, reinitiating electron transfer and ATP synthesis 187.  However, this 
leads to excessive ROS production at complexes I and III 190,191, with 
deleterious effects on mitochondrial and cellular proteins 192,193.  In particular 
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opening the mitochondrial membrane permeability transition pore (MPTP), 
which releases membrane-bound CytC into the cytoplasm, instigating cellular 
apoptosis 184,194,195.  
During ischemia, nitrite appears to confer cytoprotection via its reduction (e.g. 
by Mb) to NO, modulating mitochondrial function.  For instance, NO binds 
reversibly to the copperB/hemea3  binuclear centre of CcOx, inhibiting 
mitochondrial respiration by competing with oxygen 196-198.  This inhibition 
becomes more effective in hypoxia 199, conserving oxygen (short-term 
hibernation) during ischemia.  Furthermore, nitrite has also been shown to 
increase the efficiency of oxygen utilization by mitochondria.  Larsen et al, found 
that, following supplementation with dietary nitrate (as a source of circulating 
nitrite) in humans, mitochondria displayed an improvement in oxidative 
phosphorylation efficiency (P/O ratio) through a reduction in the expression of 
ATP/ADP translocase limiting proton leak 200. In essence ATP production 
became more efficient requiring less oxygen 200. Although the mitochondria 
were harvested from the musculoskeletal system of healthy volunteers, it is 
likely that a similar process occurs in myocardial mitochondria.  Therefore, such 
a reduction in oxygen requirements would confer partial protection of the 
myocardium during ischemia. 
On reperfusion, nitrite has direct effects on complex I and CytC.  S-nitrosation of 
complex I is known to confer cytoprotection in myocardial IRI 201,202.  Nitrite has 
been shown to reversibly s-nitrosate and inhibit complex I, attenuating ROS 
production, stabilising MPTP and inhibiting CytC release 140,151.  In addition, NO 
also prevents CytC’s release via s-nitrosylation of its haeme moiety, maintaining 
it in a hexa-coordinated membrane-stable form 203-208.   
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During normoxia, nitrite directly affects mitochondrial function, promoting 
mitochondrial fusion via protein kinase A (PKA) activation. This in turn inhibits 
dynamin-related protein 1 (Drp1) mediated mitochondrial fission 143.  Promotion 
of mitochondrial fusion and inhibition of fission is known to be cardioprotective 
during IRI 209,210.  Nitrite-mediated mitochondrial fusion resulted in an increase 
in the mitochondrial permeability potential, enhancing ROS production which 
activates AMP-activated protein kinase (AMPK) through oxidation and 
phosphorylation 143, a process which has an established protective role during 
IRI 211, and may form the basis for nitrite-mediated preconditioning.  In addition, 
nitrite mediated AMPK phosphorylation has also been shown to mitigate smooth 
cell hyperproliferation in a murine model of carotid injury. This protective effect 
is caused by AMPK’s activation of sirtuin-1, which in turn leads to the 
deacetylation of proliferator-activated receptor-γ coactivator 1α (PGC1α), a key 
receptor in the regulation of mitochondrial biogenesis 182. The promotion of 
mitochondrial biogenesis increases cellular mitochondria content contributing to 
cytoprotection. Moreover, AMPK activation has been implicated in protection in 
diabetes mellitus 212 and drug-induced cardiomyopathy 213 and may explain part 
of the mechanism of (nitrate-)-nitrite-mediated protection against doxorubicin-
induced cardiomyopathy, in addition to preservation of complex I activity, as 
demonstrated in the study by Zhu et al, 214. 
The above proposed mechanisms of exogenous nitrite-mediated pre-
conditioning resemble those observed during ischemic pre-conditioning (IPC). 
This suggests that IPC may confer its protective effects through endogenous 
nitrite-mediated production. Indeed, IPC has been shown to elevate 
endogenous myocardial nitrite levels via up-regulation of iNOS 215, and to 
  56 
reversibly s-nitrosate and inhibit complex I 201. Furthermore, the protection 
conferred through nitrite administration and IPC, have a dual temporal effect 
(termed acute and late) 151, with a similar magnitude at peak protection 143.  
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1.1.6 Alternative mechanisms of nitrite signalling  
Nitrite may also indirectly mediate its effects through the production of SNOs 
216, nitro-fatty acids 217 or directly, without the need for an intermediate or for 
conversion to NO 11,218.  
1.1.6.1 S-nitrosothiols 
S-nitrosothiols are formed through a process of s-nitrosation of cysteine, 
resulting in the addition of a nitroso group (RNO) to the sulphur atom 216,219. S-
nitrosothiols can be formed chemically through the reaction of a thiol and nitrous 
acid 219, the latter produced from nitrite as shown in Equation 1.  Alternatively, 
generation of N2O3, e.g. according to Equation 3, also nitrosates thiols (see 
Equation 13) 219.  
N2O3 + RS  RSNO + NO2
-              (13)  
In addition, NO (formed from nitrite reduction or disproportionation, as per 
Equation 4) may react directly with a thiol radical 220. The rate of this reaction is 
of a magnitude similar to that between NO and other free radicals or haems 
216,220. S-nitrosothiols may also be formed via enzymatic catalysis leading to a 
direct reaction between NO and a thiol where the metallic constituent of the 
enzyme allows for the oxidation of the intermediate thionitroxyl radical 
(RSNOH•) 216. However, many of the proposed enzymatic reactions are thought 
to be unlikely either due to unfavourable kinetics or due to the immediate 
production of nitrite in preference to the production of nitrosothiols in the 
presence of water 221.  A kinetically favourable reaction involves mitochondrial 
CytC and its production of GSNO.  Although this enzyme is confined to the 
inter-membrane space of the organelle, and GSNO is too large a molecule to 
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cross the membrane, it has been shown that a reduction in the expression of 
CytC in cells attenuates the production of SNOs 222. S-nitrosothiols are present 
in human plasma primarily as s-nitrosoproteins. Albumin’s abundance and the 
availability of its free cysteine group to nitrogen oxides makes s-nitrosoalbumin 
the most plentiful form of s-nitrosoproteins in the circulation 223. However the 
ingestion of nitrate acutely increases plasma levels of nitrate and nitrite, but not 
necessarily SNOs 224. By contrast, supplementation with nitrite (via the i.p. or 
oral route in mice) results in acute SNO-formation under normoxic conditions, 
suggesting nitrite-mediated nitrosation of thiols, independent of NO formation 11. 
S-nitrosothiols mediate their cardioprotective effects via the transnitrosation of 
many proteins, including mitochondrial complex I, as described in section 1.1.5. 
1.1.6.2 Nitro-fatty acids 
Other nitrite-derived products, such as peroxynitrite (ONOO-) lead to the 
nitration of unsaturated fatty acids. The endogenous production of these nitro-
fatty acids is enhanced under conditions of hypoxia 225.  Nitro-fatty acids are 
found in the circulation in nanomolar to low micromolar concentrations 226.  In an 
in vitro model using an isolated Langendorff rat heart, IPC was found to 
promote the endogenous generation of nitro-fatty acids 227. In an in vivo murine 
model, myocardial IRI was found to enhance fatty acid nitration in myocardial 
cells and mitochondria 228.  Furthermore, the administration of exogenous nitro-
fatty acids 15 min prior to, or at reperfusion, had a significant protective effect 
leading to a reduction in infarct size by ~46% compared to control. This 
enhanced protection is probably mediated through increased expression of the 
antioxidant enzyme haem oxygenase-1 (HO-1), elevation of MicroRNA-499 
(miRNA-499) levels, and abolition of the expression of p53 and Drp-1 229. 
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1.1.6.3 Direct nitrite signalling  
In addition, nitrite at physiologically relevant levels has been shown to directly 
induce haem-nitrosylation (NO-haem) and s-nitrosation in mammalian tissues 
(with the exception of the brain and the aorta) without the requirement for nitrite 
reduction 11. The increase in RSNO and NO-haem was dose-dependent and 
occurred despite NO-scavenging with C-PTIO. Furthermore, under the 
prevailing conditions of normal oxygen and pH, nitrite increased cGMP levels, 
attenuated CYP450 activity, up-regulated expression of heat shock 70 protein 
(Hsp70) and down-regulated expression of HO-1 11. Moreover, in a different 
study that also demonstrated nitrite-mediated dilatation of endothelium-intact 
vessels without the need for reduction to NO, the dilatory effects were 
constrained by the inhibition of cyclooxygenase (COX) 218 suggesting a role for 
the enzyme in direct nitrite signalling.   
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1.2 Comparison between inorganic and organic 
nitrate/nitrite  
1.2.1 History 
In current clinical practice, the term ‘nitrate’ refers mainly to organic nitrates, 
such as glyceryl trinitrate (GTN), with an emerging, but generally still rather 
limited, understanding of the potential relevance of inorganic/dietary nitrate. 
Other than as a useful sign of a urinary tract infection on urinalysis, ‘nitrite’ holds 
little relevance therapeutically: sodium nitrite (inorganic) is a seldom-used 
treatment for cyanide and hydrogen sulphide poisoning; whilst the organic nitrite 
amyl nitrite is a drug of abuse (poppers). 
However, to view amyl nitrite solely in this light would be to do it a great 
disservice. Amyl nitrite was first used by Sir Thomas Lauder Brunton in 1867 in 
the treatment of angina, making organic nitrates the first class of synthetic 
medical drugs 230,231. Indeed, this explains the predominance of organic nitrates, 
a position further consolidated in 1876 when glyceryl trinitrate (GTN), renamed 
from Nitro-glycerine to distance it from its origins in the manufacturing of 
explosives, was introduced by William Murrell into medical application for the 
treatment of angina 231. It superseded amyl nitrite due to its easier delivery and 
longer duration of action. Since then organic nitrates have been used 
extensively in the treatment of numerous conditions ranging from heart failure to 
anal fissures 232; and have continued to be used by physicians for over 150 
years,  despite major limitations such as tolerance and headaches. 
 Despite this predominance of organic nitrates, inorganic nitrate has a much 
longer history in the treatment of coronary artery disease (CAD), being used as 
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early as 700 AD by the Chinese 233, although it was not until the period between 
the 14th-17th centuries until the therapeutic properties of inorganic nitrate and 
nitrite were recognised in the West 13, and not until 1880  that the 
cardiovascular uses of inorganic nitrite  were recognised 233,234.  
The first known use of inorganic nitrate was as a preservative to cure foods as a 
result of its antibacterial properties.  Calcium nitrate, also known as wall 
saltpetre, was used in this capacity over 5000 years ago. Potassium nitrate 
(saltpetre) and sodium or potassium nitrite continue to be used to this day 
especially in the process of curing meats (now predominantly nitrite) and remain 
the most effective method to reduce bacterial growth and kill botulinum spores 
235. However, inorganic nitrate, added in the form of celery powder, continues to 
be used in the curing of organically produced meats, where the action of 
endogenous or artificially added bacteria eventually reduces it to nitrite 236. The 
use of inorganic nitrate and nitrite continued until the early part of the 20th 
century being prescribed indiscriminately by physicians and in copious 
amounts, to treat not only CVD, but also other conditions such as epilepsy, lung 
disease and as diuretics to treat oedema 13. This practice was discontinued 
when reports of nitrite toxicosis appeared. Concerns regarding the possible 
formation of potentially carcinogenic dimethylnitrosamine from sodium nitrite 
237,238 and nitrate 239 led them to fall out of favour and their medicinal use had 
been limited to the treatment of cyanide and hydrogen sulphide poisoning, until 
very recently.   
Richter and Mitchell, in 1880, acknowledged that amyl nitrite and inorganic 
nitrite may exert similar effects on the vasculature, an observation further 
extended by Atkinson in 1888 240. In the remainder of this chapter comparisons 
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will be made between organic and inorganic nitrate/nitrite with regards to the 
similarities and differences in their chemical structures, bio-activation pathways, 
pharmacological activity and effects, and current/possible future therapeutic 
applications. 
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1.2.2 Chemistry 
As one would expect, the differences and similarities in the biological effects of 
organic and inorganic nitrates/nitrites are closely related to their underlying 
chemical structure.  
Inorganic nitrate (NO3
-) and nitrite (NO2
-) are salts of nitric acid and nitrous acid 
respectively. The nitrate and nitrite anions are bonded to a metal cation, 
commonly Na+ or K+ (Figure 1.1). They are water-soluble and occur naturally in 
the environment through the fixation of atmospheric nitrogen and oxygen 14. 
Inorganic nitrate (and nitrite in trace amounts) thus produced then find their way 
into water and soil with inorganic nitrate taken up by plants, especially green 
leafy vegetables and beetroot 13. In addition, nitrate and/or nitrite is added to 
cured meat as a preservative 233,241. Ingestion of nitrate by humans, results in its 
reduction to nitrite largely via the entero-salivary circulation 7,233. However, the 
bulk of circulating and tissue nitrate/nitrite in mammals is formed endogenously 
via the oxidation of the NO derived from the enzymatic degradation of L-
arginine by the NOS enzymes 2,3,242. Endogenously produced NO is 
predominantly oxidised to nitrate via the actions of oxyhaemoglobin; however, 
about 20% is oxidised to nitrite via a reaction catalysed by ceruloplasmin 243. 
Furthermore, nitrite can also be formed in mammalian tissue by the reduction of 
nitrate with xanthine oxidoreductase 21. 
 
Figure 1.1: The chemical structure, activity and relationship of inorganic nitrate/nitrite   
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Organic nitrates are synthetic compounds (see Table 1.6) produced by 
nitrooxylation, a reaction between nitric acid (HNO3) and an alcohol group (R-
OH) where R- represents any organic residue (Equation 14). 
R-OH + HNO3  RONO2           (14) 
This results in the formation of esters of nitric acid (RONO2); hence, organic 
nitrates are small non-polar hydrocarbon chains attached to a nitrooxy- radical 
(-ONO2), and it is this radical which imparts its biological effects. The only 
exceptions are amyl nitrite and ethyl nitrite which bear the nitro- radical (–ONO) 
functional group instead. Furthermore, the addition of aliphatic or aromatic 
groups of variable length and volume will further affect the lipophilic properties 
of the molecule 244. The most commonly used medicinal organic nitrate is 
glyceryl trinitrate (GTN), however others include pentaerithrityl tetranitrate 
(PETN), isosorbide dinitrate (ISDN) and isosorbide mononitrate (ISMN) 245, the 
structures are displayed in Table 1.7. 
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Table 1.7: Chemical structures of organic mono-, di-, tri- and tetra- nitrates/nitrites. (ISMN = 
isosorbide mononitrate, ISDN = isosorbide dinitrate, GTN = glyceryl trinitrate, PETN = 
pentaerithrityl tetranitrate, PETrin= pentaerythritol-trinitrate, ETN = erithrityl tetranitrate). Drawn 
using ChemSketch software and adapted from 
246
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1.2.3 Pharmacokinetics 
The pharmacokinetic profiles of organic and inorganic nitrates/nitrites differ 
significantly. This difference was alluded to as early as 1928 by Bodo who noted 
that although both classes of compounds resulted in vasodilatation, the 
magnitude and duration of the effects were different for sodium nitrite and amyl 
nitrite, where the latter had a more pronounced but shorter lived effect 247. 
Many organic nitrates/nitrites, such as GTN, amyl nitrite and PETN have poor 
oral bioavailability as they undergo first pass metabolism. In the case of GTN up 
to 80 – 90% of the drug is metabolised by the liver. Hepatic glutathione 
reductase and glutathione-S-transferase progressively denature the drug 
yielding nitrate, nitrite and the other by-products, such as glyceryl-1,3-dinitrate 
which is inactive; this is in contrast to it’s metabolism in the vasculature which 
yields the active by-product  glyceryl-1,2-dinitrate 248. However, the high 
lipophilicity of organic nitrates allows for other routes of administration such as 
buccal, sublingual or trans-dermal 249. Other organic nitrates such as ISMN, 
ISDN and nicorandil have better oral bioavailability profiles with 0%, 50% and 
25% of the drug being metabolised in the liver respectively 250-252.  Once 
introduced into the blood stream, levels quickly rise which account for the rapid 
onset of action (1 – 3 min); however, they are also rapidly cleared from the 
plasma, which in turn gives them a rapid offset (15 - 30 min) 253.  
Inorganic nitrate and nitrite are hydrophilic salts which do not undergo first pass 
metabolism by the liver and so can be readily administered orally. Ingested 
inorganic nitrate is readily absorbed across the upper gastrointestinal tract; 
~75% is excreted by the kidneys, with trace amounts being secreted by sweat 
gland and ~25% concentrated in the salivary glands 6,7,14,254.  Upon secretion 
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into the oral cavity, the nitrate in the saliva is reduced to nitrite by the action of 
commensal bacteria found on the back of the tongue 18. The swallowed nitrite, 
under the influence of the acidic conditions in the stomach, becomes protonated 
to nitrous acid (see Equation 1). In turn, a proportion of the nitrous acid 
decomposes to produce NO and other derivatives (see Equations 2-4) 19,20,255. 
This reaction is further enhanced by low pH, ascorbate and polyphenols 256,257. 
After the ingestion of nitrate, either in its dietary or medicinal form, there is a 
sharp rise in the salivary, plasma and urinary levels of nitrate and nitrite 7. In the 
plasma the levels of nitrate rise within 30 min and peak at 3 hours and are 
sustained for up to 24 hours; in contrast the levels of nitrite rise more gradually 
to a significant level by 1 - 1.5 hours and plateau at ~2.5 hours and remain 
significantly elevated for up to 6 hours 165. If inorganic nitrite is ingested orally, 
its bioavailability is around 95-98% 258.  
In addition, the interaction of inorganic nitrite with alcohol under acidic 
conditions leads to the production of the organic nitrite ethyl nitrite. These 
conditions can be replicated in vivo when tissue nitrite interacts with ingested 
alcohol (red wine or distilled spirits) in the stomach 259. The quantities of ethyl 
nitrite produced are governed by the amount of nitrite in the saliva available for 
this reaction in the gut, the concentration of alcohol and the stomach acidity, the 
latter being more important. Interestingly the vasoactive effects of ethyl nitrite 
(which are mediated through NO generation) were found to be more potent than 
those of nitrite itself 259.  
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1.2.4 Metabolism and bioactivation  
The biological effects of organic and inorganic nitrates are predominantly a 
result of their NO donor capacity. Both organic nitrates/nitrites and inorganic 
nitrate are pro-drugs requiring conversion to their active metabolites (although 
nitrite as described in section 1.1.6.3 has been shown to posses direct 
signalling capabilities)11,218. The mechanisms by which organic nitrates are 
activated are not fully understood. However they are divided into two subsets 
those with high potency and 3 or more nitrate groups (GTN, PETriN and PETN) 
and those with low potency and 1 or 2 nitrate groups (ISDN and ISMN). Both 
subsets are thought to be activated via the CYP450 system leading to direct NO 
release 260,261. However, high potency nitrates at low concentrations are also 
activated by mitochondrial aldehyde dehydrogenase (ALDH-2) enzyme 262.  
Other mechanisms of activation have been suggested, these include xanthine 
oxidase, haemoglobin, glutathione-S-transferase and glutathione dependent 
reductases 263,264. Recently, it has been demonstrated that GTN mediates some 
of its effects directly through the oxidation of protein kinase G1 (PKG1) 265. 
In contrast, inorganic nitrate is metabolised via the Nitrate-Nitrite-NO activation 
pathway. Nitrite present in the blood stream is reduced directly to NO, a process 
which is enhanced in hypoxic and acidic conditions, by a number of possible 
mechanisms, which include haem-associated globins 28,44,68,97, molybdenum 
metallo-enzymes 33,112,115,266, mitochondrial proteins 47,48,50, cytochrome P450 
61,134, NOS enzymes65,132, carbonic anhydrase 63, ALDH-2 267, protons 19, 
ascorbate 256 and polyphenols 257.  Therefore, differences in the modes and 
rates of activation of organic nitrates/nitrites and inorganic nitrate/nitrite are the 
predominant determinants of their potency as vasodilators.   
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1.2.5 Structure – Activity relationship 
The pharmacophore (the component of the molecule which elicits the 
pharmacological effects) in organic nitrates is the -ONO2 group 
244. The prefix 
mono-, di-, tri-, or tetra- describes the number of ONO2 groups present in the 
molecule; recently it has been suggested that the greater the number of ONO2 
groups, the greater the potency of the drug 268. The only exception is PETN, 
which despite possessing four -ONO2 groups and demonstrating the highest 
potency in an in vitro model, displays poor clinical potency 269. This is thought to 
be related to the poor systemic bioavailability profile of its active metabolites 
PEmonoN, PEdiN and PEtriN 269,270. In addition, it is suggested that the potency 
of an organic nitrate is also dependant on its lipophilicity, which is in turn 
governed by the structure of the organic residue (R-); this is usually an alkyl- or 
an aryl- group; however, amino alkyl- groups have also been described (NH2-
(CH2)n-ONO2) 
245,246.  
Furthermore, the stereochemistry of the organic nitrate molecule influences its 
potency, as nitrates with nitrooxy-groups in the endo position are less potent 
than those with the nitrooxy-group in the exo position (see Figure 1.2 A & B), as 
the latter position makes the -ONO2 group more available for bioactivation 
(Figure 1.2) 245. However, the duration of action of nitrates with nitrooxy-groups 
in the exo position is shorter due to greater systemic and metabolic clearance 
271. Thus of the dinitrates, ISDN is used clinically and has intermediate potency 
(one exo and one endo nitrooxy-group). ISDN is metabolised to two active 
mononitrates: 5-ISMN (endo nitrooxy-group) and 2-ISMN (exo nitrooxy-group) 
(Figure 1.2 C). Whilst 5-ISMN is used therapeutically, given the endo nitrooxy-
group it would appear to be less potent than 2-ISMN; however, other factors 
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such as the position of the OH- group aid denitration; in addition, 5-ISMN has a 
lower plasma clearance and a longer half-life of ~5 hours, compared to ~2.5 
hours with 2-ISMN, and thus has a longer duration of action.  
The presence of other functional groups in the molecule will further modify their 
effects, for example nicorandil’s K+ channel opening action is thought to 
enhance vasodilatation, on the other hand, sinitrodil has improved antianginal 
action with diminished vasorelaxant activity 244,272.  
Considerations of structure-activity relationships are not relevant to inorganic 
nitrate/nitrite, given their existence as simple anions in the circulation (as seen 
in Figure 1.1). 
  









Figure 1.2: ENDO and EXO nitrooxy-group positions. (A) An example of the ENDO and EXO 
positions using dinitrates; (B) Effect of ENDO and EXO nitrooxy-group positions on relative 
potencies of dinitrates (isoiodide dinitrate (IIDN), isosorbide dinitrate (ISDN) and isomannide 
dinitrate (IMDN)); (C) Metabolism of ISDN to its two active metabolites: 5-ISMN (ENDO) which 
the form administered therapeutically,  and 2-ISMN (EXO). (Drawn using ChemSketch software 
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1.2.6 Pharmacodynamics 
The most important and well established effects of organic nitrates/nitrites are 
venodilatation and vasodilatation. At low dose, organic nitrates induce 
peripheral venodilatation, redistributing blood flow from the cardio-pulmonary 
circulation to the mesenteric and splanchnic vasculature 261. This leads to a fall 
in pulmonary artery and left ventricular end diastolic pressures and thus a 
reduction in the preload. At high dose they also induce arterial and arteriolar 
dilatation, reducing after-load 261. This effect on preload and after-load, which 
leads to a reduction in the heart’s oxygen demand, coupled with the coronary 
dilatation, leading to enhanced oxygen supply, accounts for therapeutic actions 
of organic nitrates in CAD, angina and heart failure. In addition, organic nitrates 
possess anti-thrombotic and ant-platelet effects which may enhance their 
therapeutic effects in CAD 273.  
In marked contrast to the long-established recognition of the profound vascular 
effects of organic nitrates, as recently as a decade ago inorganic nitrite was 
thought to be inert in the vasculature at physiological or near-physiological 
concentrations, being nothing more than a metabolite and biomarker of 
endogenous NO production by NOS enzymes 5. Whilst it had been 
demonstrated in 1995 that nitrite could be converted to NO in tissues such as 
the heart under hypoxic/ischemic conditions 23, with what appeared to be 
damaging effects, this was thought to have limited relevance under more 
normal physiological conditions. It was believed that the effects of inorganic 
nitrite were only mediated at markedly elevated/toxic concentrations, which 
were well recognised to result in vasodilatation/hypotension and vascular 
collapse.   
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However, following the demonstration of an AV gradient of nitrite by Gladwin et 
al, 84 suggesting consumption of nitrite across the microcirculation, and 
relaxation of rat aorta under acidic conditions by Modin et al, 27 Cosby et al, 
demonstrated that the intra-brachial infusion of near-physiological 
concentrations of nitrite resulted in vasodilatation of forearm resistance vessels 
28. Since then it has become evident that nitrite has a role as an important 
reservoir of NO in the vasculature. The associated formation of iron-nitrosylated 
haemoglobin suggested that the effects were due to the reduction of nitrite to 
NO and that deoxyhaemoglobin was involved in this process supporting the 
reduction of nitrite to NO in the small resistance arterioles, particularly of 
muscular vascular beds, where oxygen extraction from the circulation to the 
tissues is most marked. Here, the oxygen saturation of haemoglobin 
approaches the P50, the oxygen concentration at which half the haem is 
saturated with oxygen. This represents an optimum balance point between the 
greater reductive potential of haem in the R (oxy) state tetramer and the number 
of unligated deoxyhaem sites necessary for nitrite binding, which are more 
plentiful in the T state tetramer. Thus, this results in near-maximal conversion 
rates of nitrite to NO and hence vasodilatation 61,68,75,76. 
Thus in addition to vasodilatation, the enhanced reduction of nitrite to NO in 
conditions of hypoxia and low pH supports its important role in hypoxic 
signalling, and cytoprotection in IRI. This role has been supported further by the 
elegant demonstration that nitrite has a more marked dilatory effect in veins 
than resistance vessels, where the oxygen content is lower, highlighting nitrite’s 
role in oxygen sensing 29. Several ‘enzymes’ that catalyse reduction of nitrite to 
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NO under hypoxic and or acidotic conditions have been described (see table 
1.1).  
The NO produced by the reduction of nitrite activates soluble guanylate cyclase 
(sGC), an intracellular receptor and transducer that potentiates the conversion 
of GTP to cGMP 274,275. For many years it was assumed that the activity of 
nitrite on the vasculature was solely mediated through its reduction to NO and 
that nitrite has no activity of its own. Recently, however, it has been suggested 
that nitrite possesses vasodilator effects independent of those mediated by NO, 
or of known nitrite reductases 11,218,276. Besides reduction to NO, nitrite 
undergoes other reactions leading to nitrosylation of proteins 9,11, and fatty acids 
225,227,228 leading to modification their activities. (See section 1.1.6)   
Table 1.8. Summarises and compares the pharmacokinetic properties of 
organic and inorganic nitrates / nitrites. 
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Organic  Nitrates / Nitrites 
 





 Readily absorbed via 
buccal, sublingual, trans-
dermal, rectal, routes 
249
; 
also via inhalation 
277
 
 Variable  oral 
bioavailability due to 
variable rate of hepatic 
first pass metabolism 
248,253
 
 Organic nitrates with poor 






 Readily absorbed across the 
upper GI tract 
254













 Widely distributed in the 
body via the circulation 
 Blood levels rise rapidly 
with onset of action within 





 Widely distributed in the body 
via the circulation 
 25% of absorbed nitrate is 




 Following ingestion there is a 
sharp rise in salivary, plasma 
and urinary levels of nitrate 
and subsequently nitrite  
 Serum nitrite levels start to rise 
at about 1 hour and peak at 








 Rapidly metabolised by 
various enzymes leading 




 Cytochrome P450 system: 
low potency nitrate & high 




 ALDH-2: low doses of 
high potency nitrates 
262
 










 Via the Nitrate – Nitrite – NO 
pathway:  
 Enterosalivary circulation: 
nitrate reductase activity of 
bacteria on tongue generates 
nitrite:  
 Nitrite is metabolised to NO in 
the stomach and circulation 
 Circulation: haemoglobin, 
myoglobin, xanthine oxidase, 
eNOS, Aldehyde oxidase, 








 Renal failure does not 
markedly influence 




 75% of absorbed nitrate is 
excreted by the kidney 
254
 
Table 1.8: A comparison of the pharmacokinetic properties of organic and inorganic nitrates / 
nitrites. 
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1.2.7 Adverse effects 
Although organic nitrates are potent vasorelaxant drugs, their untoward effects 
continue to limit their clinical application. Adverse reactions linked to organic 
nitrates fall into two categories: acute adverse effects associated with their 
vasodilator effect such hypotension, dizziness, nausea and headache; and 
adverse effects resulting from chronic administration such as nitrate tolerance, 
increased oxidative stress and endothelial dysfunction 248,281. The mechanism 
accounting for nitrate tolerance is a complex phenomenon that is not fully 
understood. Its hallmark is the attenuated pharmacological effects of the drug 
with chronic administration. Chronic use may also lead to endothelial 
dysfunction and the development of vascular tolerance to other endothelium-
dependant vasodilators. Furthermore endothelial dysfunction triggers the 
production of ROS, which in turn further aggravates the tolerance 248. It has 
been demonstrated that the phenomenon of tolerance is consistent throughout 
most organic nitrates; the exceptions are PETN, amino-alkyl nitrates and 
nicorandil. Bioactivation of the latter two drugs is not dependant on the ALDH-2 
enzyme, which may explain this observation 246,260.  
Recent evidence has emerged suggesting the important role mitochondrial 
ALDH-2 plays in the development of tolerance. It is thought that ROS formation 
following GTN bioactivation by ALDH-2 cause oxidisation of the thiol groups, 
which form the active sites of the enzyme, thus leading to irreversible inhibition 
of ALDH-2 which in turn decreases the bioactivation of GTN. However, it is not 
fully clear if oxidation is the only process which can be implicated or if other 
metabolites may also contribute to the inactivation of ALDH-2 248,262.  
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Although inorganic nitrate/nitrite does not appear to exhibit the phenomenon of 
tolerance 282, other adverse effects, such as methaemoglobinemia (with high 
doses; also an adverse effect of organic nitrates), and a possible 
carcinogenenic effect have limited their use 13. Cases of methaemoglobinemia 
in infants after exposure to high levels of nitrate in drinking water were first 
reported in the 1940’s 283. As a consequence, concerns about the potential 
adverse effects of nitrate in water provoked the need for further regulatory 
measures aimed at limiting nitrate levels to 45 mg/L as the maximum allowed 
content 14. Methaemoglobinemia, also known as “Blue Baby Syndrome”, usually 
occurs in infants under six months of age as the result of nitrate intoxication 
from vegetables and drinking water. After nitrate reduction to nitrite, the ferrous 
ion in oxyhaemoglobin is oxidized to the ferric ion; this deprives haemoglobin of 
its oxygen binding ability. The increase of methaemoglobin in blood leads to a 
reduction in the oxygen supply to the tissues. This becomes physiologically 
significant when methaemoglobin exceeds 5-10%, and symptoms such as 
cyanosis, tachypnoea, irritability, cardiovascular problems and altered mental 
status may occur 284. The susceptibility of infants to this phenomenon is thought 
to be caused by their higher gastric pH allowing for bacterial colonisation and 
thus enhancing nitrate reduction to nitrite; the higher circulating levels of foetal 
haemoglobin which is more readily oxidized to methaemoglobin; and the 
reduced levels of the enzyme methaemoglobin reductase hindering the 
reduction of methaemoglobin back to oxyhaemoglobin 283,285,286.  
Concerns regarding the carcinogenicity of inorganic nitrate/nitrite stem from 
observations and studies performed in animals. The unexpected formation of 
the carcinogenic nitrosamine, dimethylnitrosamine in ruminants from their feed 
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of herring preserved with sodium nitrite was discovered during an outbreak of 
severe liver disease in 1961 and 1962 in Norway 237. Dimethylnitrosamine had 
previously been demonstrated to disrupt nucleic acids in the rat and cause liver 
tumours 287 and as it could be formed in vitro from secondary amines and nitrite 
mixing together in the acidic conditions of human gastric juices 288 concerns that 
ingestion of high levels of nitrite could have similar effects in humans seemed 
well founded.  
In addition to acidification of nitrite in the human stomach results in the 
formation of two potent nitrosating agents: nitrous acid, HNO2 and dinitrogen 
trioxide, N2O3 (Equations 1-4), which react with secondary amines in the diet 
producing N-nitrosamines. However whilst N-nitroso compounds were shown to 
be carcinogenic in animals 289-291, chronic feeding of nitrite to rats, even when 
diethylamine was given at the same time, did not induce tumours 292. 
Subsequently, dietary nitrate was also proposed as a potential source of N-
nitrosoamines due to its conversion to nitrite in the entero-salivary circulation 
239,293. Although numerous studies have been conducted implicating 
nitrate/nitrite in the development of cancer in humans 294-296 many other studies 
have failed to confirm this and the evidence remains equivocal 297-299. In view of 
this contradictory data, the Joint FAO/WHO Expert Committee on Food 
reviewed all the available evidence, but failed to establish a definite link 
between nitrate intake and risk of developing cancer 299,300. Furthermore, The 
World Cancer Research Fund/American Institute of Cancer Research found no 
evidence linking ingestion of vegetables which are known to be high in nitrate 
with the development of cancer 301.  
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However, there may be exceptions to this in some patient subgroups. Patients 
with Barrett’s oesophagus have been shown to have increased nitrosation at 
the gastro-oesophageal junction, an area highly associated with the 
development of adenocarcinoma 302. Furthermore there is an observed 
association between high nitrate (but not nitrite) intake with an increased risk of 
thyroid cancer 303,304. This in turn is thought to be related to the fact that the ion 
channel responsible for the transport of nitrate in the salivary gland is also 
responsible for the transport of iodide 305. This may also explain why the 
ingestion of high levels of inorganic nitrate competes with the uptake of iodine 
and may lead to thyroid hypertrophy and dysfunction 306. However, whether 
nitrate is causally associated with the development of thyroid cancer, or any 
other type of cancer, remains to be established. This is an area that has 
recently been comprehensively reviewed by Milkowski et al, and highlights the 
problems of interpreting associations between dietary factors and disease from 
epidemiological studies (such as weak associations, residual confounding etc.) 
and advises extreme caution 307. Given the potential large benefits on 
cardiovascular health, these concerns should not stall progress, but need to be 
studied in large long-term prospective studies. 
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1.2.8 Therapeutic applications in cardiovascular 
disease 
While inorganic nitrite/nitrate has numerous beneficial effects, special 
consideration will be given to its therapeutic application CVD as this allows for a 
direct comparison with organic nitrates (see tables 1.9 & 1.10).  
Organic nitrates have been used in the treatment of CVD since their 
introduction in the mid 1800’s and continue to be used to this day. In current 
clinical practice, short-acting organic nitrates are primarily indicated in the 
symptomatic treatment of MI and angina pectoris due to their rapid onset of 
action when administered sublingually. When used in long-term prevention of 
angina pectoris a washout interval of 10 hours a day is recommended in order 
to avoid tolerance. Furthermore, the development of tolerance and endothelial 
dysfunction due to the continued administration of GTN, usually for more than 
24 hours, may lead to an increased risk of re-infarction 249. In addition organic 
nitrates are also indicated for the treatment of acute cardiac heart failure and in 
hypertensive urgencies and emergencies per se and when associated with an 
aortic dissection.  
Despite a decline in the incidence of mortality from CVD it remains the leading 
cause of death worldwide. Furthermore it accounts for 48% of the total mortality 
rates in Europe 308-310.  Although the development of CVD is governed by many 
factors, the most influential modifiable life style factors include smoking, obesity, 
lack of exercise and poor diet 311. In the Dietary Approach to Stop Hypertension 
(DASH) study the supplementation of dietary intake with fruit and vegetables for 
3 weeks resulted in a reduction in both systolic and diastolic BP 312.   
  81 
Furthermore it has been suggested by retrospective studies that a diet rich in 
fruits and vegetables can improve the outcomes of CVDs 313-315. Originally these 
effects were attributed to the vitamin and antioxidant content of fruits and 
vegetables 316, however the strongest associations were found with diets rich in 
green leafy vegetables and therefore inorganic nitrate (found in high 
concentrations in these vegetables) may account for these effects 317. Indeed, 
several effects of inorganic nitrate/nitrite that would likely be beneficial in terms 
of CVD outcomes have been reported. These include vasodilatation 28, 
cytoprotection against tissue IRI 112,139, inhibition of platelet aggregation 146, 
regression of intimal hyperplasia 142, improvement in peripheral artery disease 
138,173, blood pressure reduction 146, and reduction in oxygen cost during 
exercise 318. Furthermore, the role of NO in vascular homeostasis in general is 
well established and an attenuation in its production or bioavailability is 
implicated in many of the cardiovascular disorders 135,136,319 and thus the 
provision of an alternative source of NO from nitrate/nitrite is likely to be of long 
term benefit.  
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 Organic  Nitrates / 
Nitrites 






 Short duration 
treatment has 
positive impact on 
endothelial function 
320 
 Long duration 
treatment leads to 
tolerance and ED 320 
 Enhances ATP 
release from RBC 
321,322 
 







 More effective at 
enhancing ATP 







 Leads to a reduction 
in PAP 324 
 
 Leads to a reduction 
in PAP 325 








 Has a myocardial 
protective effect if 
given and 
discontinued at a 
specific window of 
time prior to 
ischemic injury 327 
 Has a myocardial 
destructive effect if 
tolerance develops 
and is given 
throughout the 
ischemic event 328 
 
 
 Has a myocardial 
protective effect in 
I/R injury model 112 
 Improves 
angiogenesis 138 
 May improve 






 Inhibits platelet 
aggregation 329 
 Anti-platelet effect 
varies between 
different nitrates 329 





 Inhibits platelet 
aggregation 146,331 
 
 Effects are likely to 
be mediated by 
nitrite-NO 146 
Table 1.9: Comparing and contrasting the therapeutic effects of inorganic and organic nitrates/ 
nitrites in animal and preclinical models.    
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 Organic  Nitrates / 
Nitrites 










production of ROS 
332 
 
 Has a positive impact 
on endothelial 








 Leads to a fall in 
systemic BP 
 Rapid in onset 
(around 15 – 30) 
247,253 
 Limited by the 
development of 
tolerance which 





 Leads to a fall in 
systemic BP 146,162 
 Nitrate - Slow in 
onset (around 3 
hours) 
 Effects more 
sustained with no 
evidence of tolerance 
162,165 





 Leads to a reduction 
in PAP when 
inhaled 277 
 
 Leads to a reduction 





 Inhibits platelet 
aggregation with no 
evidence of 
attenuation of this 













 Treatment of acute 
pulmonary oedema 
 Treatment of Angina 
 Treatment of anal 
fissures 
 
 Antimicrobial effects 
in different parts of 
the GI tract 334,335 
 Enhancement of 
gastric blood flow 
and mucosal 
healing336,337 
 Improve exercise 
capacity318 
 
Table 1.10: Comparing and contrasting the therapeutic effects of inorganic and organic nitrates/ 
nitrites in humans.  
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1.2.8.1 Endothelial function and vasodilatation 
Endothelial function is related to the activity of endothelial NOS to generate NO 
(endothelium derived relaxing factor (EDRF)) 338,339, NO bioavailability and sGC 
signalling 319,340. An impairment in any of these pathways leads to endothelial 
dysfunction, which has been recognized as a major precursor of CVD 341,342.  
Although a short duration of treatment with GTN may have a positive impact on 
endothelial function, prolonged treatment has a negative impact by attenuating 
eNOS activity 320 and inducing the production of ROS 343. It has also been 
suggested that tolerance to GTN is caused by down regulation of mitochondrial 
ALDH-2 providing another source of ROS 344. 
In contrast, studies in mice with endothelial dysfunction, induced through a high 
cholesterol diet, demonstrated that inorganic nitrite supplementation had a 
positive impact on arteriolar endothelial function 158; In addition, nitrite treatment 
lead to the reversal of age-related endothelial dysfunction in another mouse 
model 141. In humans, similar effects were suggested when the ingestion of 
beetroot juice, or potassium nitrate lead to the prevention of IRI induced 
endothelial dysfunction as measured by flow mediated dilatation (FMD)145,146,165. 
In addition to enhancing endothelium dependent dilatation, it is worth 
considering that inorganic nitrite might enhance endothelium-independent 
dilatation by enhancing NO bioavailability, as has been demonstrated for other 
substances with anti-inflammatory effects 345.  
An alternative mechanism for the activation of eNOS is via the release of ATP 
from erythrocytes 321. The release of erythrocyte derived ATP is enhanced by 
both GTN and inorganic nitrite 322.  However, nitrite has a greater effect which 
becomes more pronounced during hypoxia 323. 
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1.2.8.2 Blood Pressure 
Studies undertaken in healthy volunteers demonstrated a significant reduction 
in BP following the ingestion of inorganic nitrate 146,162,165. Ingestion of nitrate-
rich beetroot juice leads to blood pressure reduction that was maximal at 
around 2.5 – 3 hours; this is consistent with the peak nitrite plasma levels. In 
addition, when the entero-salivary circuit was interrupted, by spitting or by 
antibacterial mouthwash, there was no significant rise in plasma nitrite levels 
and the blood pressure lowering effects were abolished, providing further 
evidence that these effects were a result of the increase in circulating nitrite 
levels 146,346. Once in the circulation inorganic nitrate is estimated to have a half-
life between 5 - 8 hours, a result of its active reabsorption in the proximal renal 
tubule 347.  The half-life of an oral dose of nitrite on the other hand has been 
demonstrated to be around 110 seconds 348. In addition nitrates BP lowering 
effects of nitrate were dose-dependent 165. Although these studies were 
conducted in healthy volunteers these effects were also replicated in patients 
with hypertension 116.  
In a rat model of hypertension, induced through a unilateral nephrectomy and a 
chronic high salt diet, intervention with high dose nitrate resulted in a reduction 
in BP which was greater in magnitude than that observed in normotensive rats. 
In addition this effect was maintained for the 8 week duration of the study 
indicating the lack of any tolerance 349. Furthermore, the rats treated with nitrate 
supplementation demonstrated a reduction in renal hypertrophy, fibrosis and 
injury leading to the mitigation of protein urea 349. These effects of reduced 
hypertrophy and fibrosis were not exclusive to renal tissue but were also 
observed in the myocardium, albeit to a lesser extent. The protective effects on 
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cardiac and renal remodelling evoked by nitrate supplementation are likely to be 
due to the reduction in oxidative stress rather that the reduction in BP per se 349. 
Also, sodium nitrite has been shown to have antioxidant effects: supplementing 
the drinking water for 4 weeks in two-kidney one-clip (2K1C) hypertensive rats 
with sodium nitrite resulted in a dose dependent decrease in BP associated with 
an inhibition of NADPH oxidase activity 161. While organic nitrates may be 
effective in lowering BP, and are used, for example, in the management of 
acute hypertensive emergencies, the effect is often variable, and longer term 
use is limited by the rapid development of tolerance. 
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1.2.8.3 Pulmonary hypertension 
Both organic nitrates and inorganic nitrite have been shown to affect pulmonary 
arterial pressure (PAP). In studies on anesthetised dogs, intravenous GTN was 
found to have no effect on PAP, though inhaled GTN lead to a reduction in PAP 
350. However, a more recent study in the same animal model using higher doses 
of intravenous GTN found that it decreased PAP 324. The use of inhaled GTN in 
humans also resulted in a reduction in PAP 277,351. It should be noted that in all 
these studies the GTN was administered for long enough for the effects of 
tolerance to become evident. 
Dietary nitrate supplementation in a mouse model improved PAP in a mouse 
model of the disease 352. A study in sheep has demonstrated that inhaled 
inorganic nitrite also leads to dilatation in pulmonary vascular beds ameliorating 
pulmonary hypertension 326. And in a canine model of pulmonary embolus the 
administration of intravenous nitrite had similar effects on PAP 325. The use of 
inorganic nitrite in human studies resulted in vasodilatation in the pulmonary 
vasculature leading to reduction in PAP 278,279.   
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1.2.8.4 Myocardial Infarction 
 A key determinant of post MI mortality and morbidity is the degree of left 
ventricular systolic dysfunction, which is in turn directly determined by the infarct 
size 353. Besides reperfusion therapies, there are two strategies that could 
potentially reduce infarct size. The first is preconditioning, either ischemia-
induced or pharmacological; first described in 1986, IPC describes the 
protection acquired by tissue from the effects of a prolonged ischemic event, 
when the same tissue is subjected to non sustained periods of ischemia 354. In 
addition, protection can be afforded if the repeated ischemic insult occurs in a 
different organ, the phenomenon of remote IPC 355. The second strategy 
involves the attenuation of further cell death and apoptosis incurred following 
the reestablishment of coronary perfusion (IRI) a phenomenon known as post 
conditioning 356. 
Nitric oxide has been demonstrated to play an important role in IPC 357-359. GTN 
was used as a NO donor in this disease model in animals and was found to 
impart a significant degree of myocardial protection 327. In this rabbit model, a 
60 min intravenous infusion of GTN was discontinued in different groups at 
different time points (1, 24, 72 and 96 hours) prior to the onset of the ischemic 
insult. There was no group in which GTN treatment was continued throughout 
the ischemic insult as it was felt that this would represent direct cardio-
protection. A myocardial protective effect in the 1 hour and 96 hour groups was 
comparable to that in the group treated with conventional IPC. The protective 
effect in the 24 and 72 hour groups was greater than the control. 327.  
However, in a different study, conducted in a rat model, the continuous delivery 
of GTN throughout the ischemic insult lead to an increase in the infracted area 
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from 45% to 59% 328. On the other hand the discontinuation of the GTN 
treatment 3 hours prior to the ischemic event caused a decrease in the infarct 
size from 45% to 33% 328. This unusual finding may be explained by the results 
of more recent studies which demonstrated that ALDH2 is involved in protecting 
the myocardium from IRI damage when it is up-regulated, but the reverse is true 
when it is down-regulated 360,361. One must note that the above studies have 
been conducted in animal models and the findings are yet to be validated in 
humans. However, clinical trials have not demonstrated any clear benefit of 
organic nitrates. Although the Vasodilator Heart Failure Trial (V-HEFT) 
suggested a small improvement in outcomes between the ISMN-hydralazine 
and placebo, this did not reach statistical significance 362. A possible 
mechanism relates to observation from in vitro experiments which suggest that 
hydralazine may inhibit the development of tolerance 363. Whilst in the fourth 
International study of Infarct survival (ISIS-4), 30 days administration of ISMN 
post infarct appeared to be safe, but had no mortality benefit vs. placebo 364. 
However, two more recently published studies demonstrated increased cardiac 
events and worse outcomes in some patient populations treated with ISMN 
365,366.  Therefore, the current place of organic nitrates as a symptomatic 
treatment of patients with CAD may need to be investigated further.  
Following an initial indication that inorganic nitrite was deleterious in a model of 
IRI 23, nitrite was found to have profound cytoprotective effects, significantly 
decreasing infarct size and restoring cardiac function in an in vitro rat  
myocardial IRI model 112, which was substantiated in an in vivo model 137. Many 
subsequent studies have confirmed these cytoprotective effects in other animal 
models and other organs such as the brain, liver and kidneys in addition to the 
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heart 139,367,368. Whilst these effects are dose dependent, it is striking that low 
micromolar concentrations are effective, indeed dietary nitrate and nitrite 
depletion results in increased IRI in the liver 367 and the heart 150. Furthermore 
long-term administration of sodium nitrite has been demonstrated to enhance 
angiogenesis in ischemic tissue 138. In addition, treatments with inorganic nitrite 
lead to improved outcomes in a mouse model of cardiac arrest 140. Although 
such findings in animal models provided considerable promise of inorganic 
nitrite as a treatment of MI in humans, a recently published trial showed no 
increased benefit from intra-venous nitrite administration 5min prior to 
reperfusion therapy 144 (as described in section 1.1.4.5). However, the results of 
another trial where nitrite was administered intracoronary immediately prior to 
revascularization are still awaited 180.     
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1.2.8.5 Platelet function 
 In addition to playing an important role in normal coagulation and vascular 
healing, platelet activation and aggregation also plays a key role in the 
pathophysiology of atherosclerosis, atherothrombosis and acute coronary 
events 369-371.  
An early study conducted by Schafer et al, investigated the effects of GTN and 
ISDN on platelet function 329. The investigators found that GTN inhibited platelet 
aggregation and that this inhibition was both dose and time dependent. 
Furthermore these effects were reversed when the exposure of the platelets to 
the GTN was abolished. These effects seemed to be mediated by disrupting the 
arachidonic acid – thromboxane A2 pathway and were not related to an 
increase in intra-cellular cyclic adenosine monophosphate (cAMP); ISDN had 
similar effects, however those of GTN were more pronounced 329. The 
antiplatelet effect of GTN also appears to be partly dependent on activation via 
XOR 330. Furthermore, the effects of GTN on platelet aggregation do not appear 
to be affected by chronic administration and the development of vascular 
tolerance 333. However, continuous administration of GTN for 3 days via trans-
dermal patch lead to increased production of superoxide by platelets 372. The 
clinical applications of this are yet not fully clear as clinical studies have 
demonstrated conflicting results; for example a further study which evaluated 
the effects of organic nitrates (GTN / ISDN) on platelet function in patients 
undergoing coronary artery bypass grafting (CABG) failed to demonstrate any 
measurable effects on platelet function when using bedside coagulation 
parameters 373.  
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Whilst inorganic nitrite was originally thought to lack any effect on platelet 
aggregation, as supported by studies in the rat 11, inorganic nitrate was found to 
inhibit platelet aggregation in humans 146,331. Originally it was proposed that 
SNO formation might play a role 331; however SNOs were not detected in the 
systemic or portal circulations. In humans, it became clear that the effect of 
nitrate on platelets was dependent on its conversion to nitrite, as spitting of all 
saliva for 3 hours abolished both the rise in serum nitrite levels and the 
antiplatelet effect 146.  
 
1.3 The vascular bed, nitrite and the role of 
deoxyhaemaglobin 
The arterial tree functions as a conduit, transferring blood from the heart to the 
organs and the extremities, and a cushion, dampening the pulsatile nature of 
blood ejected from the heart 374. Thus, it delivers oxygen and nutrients to the 
peripheral organs at a steady rate and pressure 374. The branching design 
coupled with a constant wall shear rate allows the arterial vessels to operate as 
the optimal conduit system with a minimum of work requirement 375. The larger 
conduit vessels have intrinsic elastic properties, making them more compliant 
and allowing them to expand in systole and recoil in diastole propelling blood 
onwards and dampening the oscillatory flow in the process 376. The smaller 
muscular arteries have a higher prevalence of smooth muscle cells allowing 
them to dilate providing a low resistance path to the organs and the extremities 
376. Arterioles are responsible for further smoothing of the pulsatile flow to a 
more laminar flow in addition to the regulation of blood distribution to organs 
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and within an individual organ. Furthermore, by controlling the peripheral 
vascular resistance, arterioles determine the mean blood pressure.  
This level of control on the part of resistance arterioles requires a sophisticated 
level of regulation in which NO plays an important part, acting as an 
endogenous dilator produced by the vascular endothelium offering background 
dilatation of the arteriolar bed, moreover, the production of NO can be changed 
in response to variations in blood flow which alters the shear stress377. 
Nitric oxide donors cause a dilatory effect in muscular conduit arteries that is 
more pronounced than in resistance arterioles . It has been proposed that this 
heightened sensitivity to NO donors is consequent to the minimal basal levels of 
endogenous NO found in conduit vessels 378. It is suggested that endogenously 
produced NO down regulates the expression of sGC and diminishes its 
sensitivity to NO . In addition, NO reduces G kinase expression and enhances 
the activity of phosphodiesterase V, further desensitising the vascular smooth 
muscle cells.  Hence, the dilatory selectivity of NO donors for a particular vessel 
type may in part be dependent on the basal levels of NO found in each vascular 
bed.  
Indeed, the organic nitrate GTN is a selective dilator of muscular conduit 
arteries . However. It has been suggested that Inorganic nitrite is dependent on 
hypoxic conditions to facilitate its reduction to NO, via the actions of 
deoxyhaemoglobin amongst other enzymes. However, nitrite’s observed 
vasodilatation of resistance arterioles  does suggest that nitrite may act as an 
NO donor under conditions of near normal oxygen tension. Thus it is probable 
that nitrite may continue to act as an NO donor under conditions of normal 
oxygen tension and in the absence of high levels of deoxyhaemoglobin.  
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The proposal that nitrite is mainly reduced by deoxyhaemoglobin to NO  may 
well  hold true for the prominent vasodilation observed in veins, where 
deoxyhaemoglobin is prevalent, and for the enhanced dilatation of resistance 
arterioles when comparing hypoxia to normoxia . However, the role 
deoxyhaemoglobin plays in physiological systems remains controversial as it 
does not adequately explain nitrite's actions on the resistance arterioles under 
conditions of normoxia, where modest dilatation occurred , as these vessels still 
display oxygen tensions (and levels of deoxyhaemoglobin) comparable to those 
found in other segments of the arterial tree.  
In fact, when doses of 10 μM of sodium nitrite (designed to mimic near 
physiological levels) were add to rabbit aorta (Ao), inferior vena cava (IVC) and 
pulmonary artery (PA) dilatation to all vessel types was evident 379. Under 
conditions of normoxia the PA dilated more than the Ao (the IVC response was 
variable). However, under conditions of hypoxia, the Ao dilatation was 
significantly greater than that observed in the PA and the IVC.  During hypoxia 
the nitrite-induced dilatory response was enhanced in all vessels, however, this 
increase was more marked in the Ao (700%) than in the PA (60%); furthermore, 
these effects were independent of the presence of haemoglobin 378. This 
suggests that deoxyhaemoglobin plays a relatively minor role. Instead, these 
differences may be related to the significantly greater smooth muscle mass in 
the Ao when compared to the two other vessels. Indeed, this would be 
consistent with the has been suggestion that nitrite-induced dilatation under 
aerobic conditions is mediated via sGC and/or other haem enzymes . 
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1.4 Summary  
Nitrite is both a metabolite of endogenously produced NO and the largest 
directly accessible mammalian source of the messenger.  Biologically active NO 
can be liberated from this pool when nitrite is enzymatically reduced via the 
actions of a number of candidate proteins.  The relative contribution of these 
proteins to nitrite’s reduction is dictated by its tissue distribution, level of 
expression, and modifiable activity dependent on the prevailing conditions. 
Indeed, they all exhibit increased activity under conditions of hypoxia and/or 
acidosis, making nitrite a selective donor of NO in hypoxic/ischemic tissue, 
compensating for the diminished NOS activity. Nitrite, either through reduction 
to NO, or via direct signalling, modifies mitochondrial structure and function 
improving a host of cardiovascular disease processes.  
Although organic nitrates/nitrites also mediate their effects principally via NO 
and share many similarities with inorganic nitrite (and nitrate) they also have 
striking differences in terms of their pharmacokinetics, pharmacodynamics, 
chemical structure and mode of activation with associated differential effects on 
their modification of cardiovascular function and disease.   
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1.5 Hypothesis  
The cardiovascular actions of inorganic and organic nitrates / nitrites on conduit 
and resistance vessels are believed to be different. The organic nitrate GTN 
(which is able to act as an NO donor under conditions of normoxia) is a 
selective dilator of muscular conduit arteries , the accepted mechanism by 
which GTN selectively lowers central blood pressure 378. It has been proposed 
that inorganic nitrite, however, is dependent on hypoxic conditions to facilitate 
its reduction to NO . Moreover, the suggested requirement for hypoxia to 
facilitate nitrite’s action, in addition to oxygenated haemoglobin and myoglobin 
being avid scavengers of nitrite-derived NO, suggests that nitrite will lack any 
activity in conduit vessels. However, under conditions of normoxia, nitrite has 
been shown to effectively dilate resistance arterioles .  And although a degree 
of oxygen extraction does occur at the level of resistance arterioles  the levels 
of deoxyhaemoglobin in these vessels is not too dissimilar from that in conduit 
vessels. Thus although the current literature suggests that inorganic nitrite is a 
selective hypoxia-dependent resistance arteriolar dilator, with minimal effect on 
conduit arteries. We propose that inorganic nitrite may have a dilatory effect in 
conduit vessels that would become more pronounced under conditions of 
induced hypoxia.  To test this hypothesis a number of studies were conducted 
where an intra-arterial or an intra-venous infusion of sodium nitrite was 
administered; with the concomitant measurement and assessment of vascular / 
hemodynamic parameters; selectivity in normoxia, hypoxia and hyperoxia; and 
effect of inhibition of AO with raloxifene or inhibition of CA with acetazolamide.  
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Chapter 2 
Chapter 6 : Methods   
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2.1 Volunteers 
The studies were approved by the St Thomas’ Research Ethics Committee 
(South East London REC2) and NRES Committee London – Westminster. 
Subjects were healthy male volunteers recruited from the community. Informed 
written consent was obtained from all the participants.  
2.2 Reputability and reproducibility 
Once recruited, volunteers were allocated to one or more groups of studies. Pre 
set dates were agreed upon in which the volunteers were to present to the 
research facility. If more than one visit was required, in order to compare the 
effects of different interventions, then visit dates were set to be at least one 
week apart. The order of the intervention being administered during each visit 
was randomised in an equal fashion so that the number of interventions 
administered first were the same within a complete study set (with 3 visits a 
randomised balanced Latin square design was implemented). The participants 
were blinded to the intervention being used in each visit. 
Data acquired from each visit was saved under the allocated participant number 
and the visit order (i.e. 1st, 2nd or 3rd) without any indication of the intervention 
applied.  Analysis of the data set was conducted only at the conclusion of the 
entire study (i.e. when all the participants completed all of their visits). Analysis 
was first conducted by the investigator, and then repeated by a second 
experienced party, which was blinded, with no access to the randomisation 
table containing the order of interventions applied in each visit. 
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2.3 Standard study protocol  
Participants were asked to avoid ingesting nitrate-rich foods (including green 
leafy vegetables, beetroot and processed meats), caffeine, smoking and 
undertaking heavy exercise for 24 hours prior to the study. They were also 
instructed to fast overnight (though encouraged to take clear fluids to avoid 
dehydration). The studies were conducted at a similar time of the day, for 
repeated visits in the same subject, under controlled temperatures (23 - 27 °C) 
and with minimal sensory stimulation to minimise confounding. For intra-arterial 
(i.a.) studies, the brachial artery was cannulated using a 27 gauge needle 
(Cooper’s Needle Works, Birmingham, UK®). This part of the procedure was 
performed with the use of local anaesthesia and under strict aseptic techniques. 
For intravenous (i.v.) studies, an 18 gauge cannula in an antecubital fossa vein 
was used. On successful cannulation the needle was secured in position and a 
saline infusion was commenced at a rate of 1 ml/min (Injectomat Agilia syringe 
driver, Fresenius Kabi, Homburg, GR®). Following an initial equilibration period 
of 15 min and recording of baseline measurements with 0.9% saline, the effects 
of i.a./ i.v. Sodium nitrite (Martindale Pharmaceuticals, UK and Ipswich Hospital 
Pharmacy Manufacturing Unit, UK®)/ GTN (Hospira Ltd, UK®) on radial artery 
(RA) diameter, forearm blood flow (FBF) and systemic haemodynamic 
parameters were assessed as described in detail in the following sections. 
Blood samples for the assessment of local concentrations were taken using an 
18 gauge cannula placed in the radial vein of the infused arm. A similar sized 
cannula placed in the antecubital vein of the control arm was used for the 
aspiration of blood samples intended for the assessment of systemic spill over.    
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2.4 Measurement of conduit and resistance 
vessel function 
2.4.1 Measurement of local radial artery diameter (conduit 
vessel) 
An Acuson-Aspen advanced 2-dimensional ultrasound (2D US) machine with a 
10 MHz Linear probe (Siemens GR®) was used for direct imaging of the radial 
artery (Figure 2.1). The probe was fixed in position using an adjustable 
magnetic flexible stand (Mitutoyo JP®). Facilitated by ECG triggering, images 
were acquired at the end-diastolic phase for the duration of 120 seconds at a 
rate of 1 frame every 3 seconds, giving a total of 40 frames per sequence of 
acquisition. The Radial artery diameter for each individual frame was measured 
using computer aid edge-to-edge detecting software (Brachial analyzer, Medical 
Imaging Applications®) and the mean of the measurements of the 40 frames 
was used to give the vessel diameter at that time point (Figure 2.2).  
 
Figure 2.1: Diagrammatic representation of 2-D US imaging used for the assessment of RA 
diameter. 2-D US – 2-dimensional ultrasound, RA – Radial Artery.   
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Figure 2.2: 2-D US images depicting a single acquisition frame. The RA lumen and RA proximal 
and distal and vessel wall edges can be clearly seen. The dashed box delineates the segment 
being measured by the software. A) A single acquisition frame of the RA at baseline during 
saline infusion (measures 2.83mm). B) A single acquisition frame of the RA following infusion 
with inorganic nitrite 2.6 μmol (measures 3.37mm). This is equivalent to dilatation of 16%. 2D 









Measured segment  
Measured segment  
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2.4.2 Measurement of local forearm blood flow (resistance 
arterioles) 
Although arterial flow can be calculated from the measurements of arterial 
diameter (acquired via 2D US as described in 2.3.1) and blood velocity 
(measured using Doppler US) 378 the technique suffers from a number of 
limitations. It is heavily operator dependant, requiring extreme precision during 
repeat studies, as small errors in the measurement of arterial diameter will lead 
to magnification of the error when calculating flow; this is in addition to the 
inability to generate a dose response curve for the effects of drugs infused 
locally on the resistance vessels 378.  
Venous occlusion plethysmography (VOP) however, provides a simple, 
accurate and reproducible assessment of FBF. And when combined with the 
minimally invasive procedure of intra-arterial drug administration, allows for 
detailed analysis of the vasoactive pharmacological effects of a drug 378.  
2.4.2.1 Venous occlusion plethysmography 
First described by Hewlett & van Zwaluwenburg in 1909 380, combining venous 
occlusion with occlusion plethysmography is now an established method for the 
measurement of FBF. The key principal is that the occlusion of venous return 
from the arm without affecting arterial inflow will lead to tissue swelling, as blood 
continues to enter the limb but is unable to leave. Moreover, the tissue swelling 
(or increase in forearm volume) over time, remains linear for as long as the 
veins are not fully distended, and the rising venous pressure remains less than 
that of the occluding pressure 378. Measuring this linear rate of increase in 
forearm volume gives an indication of the rate of arterial inflow.  
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Originally the measurement of tissue swelling was awkward and challenging 
relying on air and then fluid displacement 378. However, in 1953 Whitney refined 
the technique by demonstrating that changes in limb volume could be measured 
using a mercury-in-rubber elastic strain gauge 381, making the technique far less 
cumbersome and gaining it wide appeal.   Whitney surmised that excluding the 
circulation of the hand approximated the shape of the forearm to that of a 
cylinder allowing its volume to be calculated by the following equation:  Volume 
of a cylinder (V) = circumference x the height (or length). Therefore V = πd xl 
(where (d) is the diameter and (l) the length) Figure 2.3. As the length of the 
arm remains constant, the rate of change in circumference is proportional to the 
rate of change in volume  (i.e. Δ Volume = Δ circumference). 
 





Figure 2.3: Volume of a cylinder is equal to its circumference (πd) multiplied by its length (l).   
To measure the change in circumference Whitney employed the elastic 
mercury-in-rubber strain gauge, such that alterations in the circumference of the 
forearm at the level of the strain gauge would lead to alterations in its length; 
this in turn would cause a (recordable) proportional variance in the strain 
gauge’s resistance 378. This technique has changed little over the years being 
only recently refined by the introduction of computerisation giving rise to traces 
as seen in Figures 2.4 and 2.5.     
 d 
l 
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Figure 2.4: A venous occlusion plethysmography computer enhanced tracing taken at baseline (i.e. during saline infusion). The above tracing (Channel 1) is 
of the intervention (infused arm) and the bottom tracing (Channel 2) is of the control (non-infused) arm. The rate of increase in forearm volume in both arms 
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Figure 2.5: A venous occlusion plethysmography computer enhanced tracing taken during inorganic nitrite infusion. The above tracing (Channel 1) is of the 
intervention (infused arm) and the bottom tracing (Channel 2) is of the control (non-infused) arm. The rate of change in the volume of the intervention arm has 
increased from that seen on baseline (Figure 2.4) and is clearly greater than that of the control arm. The points at which the venous cuffs are inflated and 





  106 
In addition to approximating the volume of the forearm to that of a cylinder, 
exclusion of the hand’s circulation is required in view of the different 
pharmacological and physiological responses displayed by its vasculature when 
compared to that of the forearm 378,382. The difference is consequent to the high 
number of arterio-venous shunts contained in the hand and the larger 
proportion of blood flowing through the skin; whereas in the forearm the bulk of 
blood flow (~50 - 70%) is through the muscle 382,383.  
Excluding the hand’s circulation is achieved by rapidly inflating a cuff placed 
around the wrist to a supra-systolic pressure (~170 - 180 mmHg). The wrist 
cuffs are inflated for around 30 - 60 sec prior to taking measurements to allow 
FBF to reach a stable and steady state 384. Occlusion of venous return is 
accomplished via inflating a cuff placed around the upper arm to a pressure that 
is supra-venous but well below the diastolic pressure (~40mmHg) 385 (Figure 
2.6). Although the wrist cuffs remain inflated throughout the time period in which 
the measurements are taken (this should be minimised as the hands remain 
ischemic for the duration) the venous cuffs are inflated for 10 seconds then 
deflated for ~5 seconds to allow the veins to empty and the recording to return 
to base line 386 (Figures 2.4 & 2.5). To facilitate rapid emptying once the cuffs 
are deflated, the arm is supported using foam pads and the forearm positioned 
slightly above the level of the right atrium. The measure of blood flow in the 
roughly cylindrical area delineated by the two cuffs is expressed in ml of flow 
per min per 100 ml of tissue (ml/min/100 ml tissue).  
Combining intra-arterial drug administration with VOP, indirectly assess the 
vasoactive effects of drugs on the tone of resistance vessels, by measuring the 
changes in flow 382,387 (Figure 2.6).  However, the relationship between changes 
  107 
in flow and vascular tone will only hold true as long as there are no significant 
changes in arterial BP, as a vessel’s resistance results from the interplay of the 
underlying tone and the distending pressures 388.   
 
Figure 2.6: Diagrammatic representation of the 2D US, venous occlusion plethysmography and 
intra-brachial infusion set up to measure changes in conduit (RA) and resistance (FBF) vessel 
changes. 2D US – 2-dimensional ultrasound, RA – Radial Artery, FBF – fore arm blood flow.  
It is important to note that by altering FBF, a vasoactive drug will also cause 
changes in its own concentrations found in the plasma; thus a vasodilator which 
enhances FBF will lead to a fall in plasma concentrations, whereas a 
vasoconstrictor will reduce FBF and increase plasma concentrations 389.  
Hence, the vasoactive effect of a drug is expressed in the form of a cumulative 
dose response curve not the concentration of the drug in the plasma. Although 
the vessels can reach maximal dilatation (or constriction) meaning that there is 
a sigmoid relationship, at the lower doses used the association between the 
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response and the log of the infused dose is a linear one 387. Results can be 
expressed as an absolute change from baseline FBF or as a change in ratio 
between the infused arm and control arm. The latter allows for the negation of 
any external factors that may influence general basal tone. However, although it 
may seem that using the non-infused arm as a control when expressing and 
analysing the data is advantageous, allowing for better reproducibility, this only 
seems to hold true when evaluating vasoconstrictors.  When assessing 
vasodilators the data is improved when expressed in absolute terms using the 
infused arm only, as small changes in the FBF in the control arm will have a 
magnified effect on the FBF ratio in the high flows induced by the drug 390. 
Indeed percentage change in ratio of FBF was found to be more reproducible 
when assessing the effects of vasoconstrictors 391.  However, when assessing 
the effects of vasodilators it was found that reproducibility was enhanced when 
the changes were quoted as absolute values of FBF rather than as a 
percentage change in the FBF ratio 392.   
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2.4.3 Measurement of radial artery and forearm blood 
flow protocol 
The volunteer remained supine for the duration of the study. Pressure cuffs 
were placed around the upper arms and the wrists. The cuffs themselves were 
connected to E20 Rapid Cuff Inflators, which in turn were supplied by an AG101 
Cuff Inflator Air Source (Hokanson Inc. WA US®). The circumference of the 
forearms were measured, using a measuring tape, and an appropriately sized 
mercury-in-silastic strain gauge was placed around each forearm and 
connected to an EC6 Plethysmograph (Hokanson Inc. WA US®). The wrist cuffs 
were inflated to supra-systolic pressure (180±2 mmHg) to exclude the 
circulation in the hand. After a 30-60 sec pause, to allow the changes in the 
forearm circulation to reach equilibrium, the cuffs around the upper arm were 
inflated to supra-venous pressures (40±2 mmHg) and deflated a number of 
times in cycles consisting of ~10 sec inflation and ~5 sec deflation. The degree 
of change in the circumferential size of the forearm measured by the mercury-
in-silastic strain gauge was acquired by channelling the signal through the EC-6 
Plethysmograph, and recorded and analysed using Chart 5 software® (see 
figures 2.4 & 2.5).  
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2.5 Measurement of systemic haemodynamics  
Following a minimum period of 5 min laying supine, baseline readings of non-
invasive measurements of the following systemic haemodynamic parameters 
were performed: pulse wave velocity (PWV), brachial-femoral (bfPWV) was 
measured over the brachial to radial path from simultaneous pressure cuff 
recordings at each site using the Vicorder system (Skidmore Medical Ltd, Bristol 
UK®). The path distance was taken from the proximal edge of the upper arm 
cuff to that of the wrist cuff.   Peripheral BP and heart rate were also measured 
(IntelliVue MP30, Phillips, NL®): during forearm blood flow studies, a thigh cuff 
was placed over the arm cuff, however, measurements were also taken at 
baseline and at the end of the infusion with the BP cuff placed directly on the 
arm; these latter measurements were used to calibrate the Finometer (Finapres 
Medical systems, Amsterdam NL®) used to determine central blood pressure, 
augmentation index and heart rate. An average of 2 readings (rather than 3) 
was taken for the final results, due to time limitations. Measurements were 
repeated during and/or at the end of the study. In calculating the central pulse 
pressure (cPP), the peripheral diastolic BP (DBP) measurement was used, as 
central DBP was not recorded. However, DBP changes by only 1-2 mmHg from 
the aorta to the periphery, and therefore our measurement of peripheral DBP is 
a close estimate of central DBP. In addition, SpO2, SpMet (Radical-7, Rainbow, 
CA, US) were measured continuously in studies using higher doses of nitrite or 
in those in which hypoxia or hyperoxia were induced.  
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2.6 Hypoxia/normoxia/hyperoxia studies Protocol 
A continuous positive airway pressure (CPAP) mask, fixed with a one-way 5.0 
cm H2O positive end expiratory pressure (PEEP) valve system, was securely 
fitted around the participant’s nose and mouth. The mask was connected via 1.5 
meters of tubing to either: (i) a room air port (normoxia), (ii) a 100% oxygen port 
(hyperoxia) or (iii) a 12% oxygen/ nitrogen balanced gas mix cylinder (hypoxia). 
When the latter was used, the aim was to achieve stable arterial oxygen 
saturation levels (as measured by pulse oximetry) above 83%, as previously 
described by Maher et al. 393. All three inhaled gases were delivered at a 
pressure of 1.5 to 2 bars and the flow of gas was adjusted to achieve the 
desired oxygen saturations at a level that was comfortable for the volunteer (15 
- 20 litre/minute). At the completion of the study an arterial blood gas sample 
was aspirated, into a heparinised gas syringe, via the brachial needle and 
analysed through a blood gas machine.  
It should be noted that a number of limitations of this study design do persist. 
The use of a facemask resulted in a sudden drop in inspired oxygen levels and 
hinders the maintenance of a steady state of hypoxia. Acute hypoxia (with 
oxygen concentrations of < 17%) affects haemodynamics, inducing tachycardia 
394 and increasing cardiac output and BP 386. In addition, it affects respiratory 
physiology causing pulmonary hypertension and hyperventilation 382.  
Moreover, prolonged exposure to hypoxia (up to 2 hours) is required to allow for 
equilibration and the attainment of a steady physiological state , however, the 
need to immobilise the participants for the total duration of the study restricted 
it’s length, limiting the interval of exposure to hypoxia.   
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2.7 Measurement of plasma nitrite and s-
nitrosothiols 
A number of techniques are available to measure nitrite and other NO-related 
species in biological samples, either directly (e.g. capillary zone electrophoresis, 
high-performance capillary electrophoresis and high-performance liquid 
chromatography) or indirectly (e.g. Griess reaction or chemiluminescence 
detection method) 388. However, ozone based reductive chemiluminescence 
detection (CLD) has become the method of choice for the detection and 
quantification of nitrite and other NO metabolites in biological matrices due to its 
sensitivity and specificity when combined with different reductive methods 
382,395. 
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2.7.1 Chemiluminescence detection 
Originally developed by Cox and Frank in 1982, CLD measures nitrite levels in 
fluid samples indirectly by reducing it to NO and measuring the stoichiometric 
amount of NO that is released 382. It has been reported to detect levels of nitrite 
as low as 5nM in biological fluids 388.  
Cox and Frank noted that in the presence of an acid (they used glacial acetic 
acid) nitrite reacts to produce free nitrous acid (see Equation 1), the nitrous acid 
can then further be protonated to H2NO2
+ (Equation 15) which exists in 
equilibrium with a nitrosonium cation (NO+) (Equation 16).    
H+ + HNO2  H2NO2
+                                                                                  (15) 
H2NO2
+  NO+ + H2O                                                                                  (16) 
However, they also noted that to release NO a reducing agent was required, 
and for that they used potassium iodide (KI), where the free iodide anion 
(Equation 17) reacts with NO+ converting it to NO via a nitrosyle iodide (ONI) 
intermediate (Equations 18 & 19). 
KI  I
- + K+                                                                                                      (17) 
NO+ + I-  ONI                                                                                                (18) 
2ONI  2NO + I2                                                                                             (19) 
This method of quantification is not exclusive to nitrite alone as different redox 
agents can be used; the chemical nature of which depends on the specific NO-
species being measured. Using the appropriate reducing agent allows 
chemiluminescence to be highly selective with a level of imprecision reported to 
be as low as 5% 382.  
A glass purging-vessel (Figure 2.7) is used to hold the redox chemical solution. 
The sample which is to be tested is injected in 50 μL – 200 μL aliquots directly 
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into the purging vessel so that the redox agent reduces the nitrogen containing 





Figure 2.7: Diagrammatic representation of a purge vessel set up. The stopcocks in this 
diagram are all depicted in the closed position. When running an assay the inert gas inlet and 
NO outlet stopcocks should be open. The drain stopcock is opened when the redox chemical is 
due to be changed. The needle valve is used to adjust the cell pressure and control the rate of 
flow of the inert gas into the reaction chamber. NO – nitric oxide.  
 
An inert gas is purged through the system forcing the NO out of the solution, 
and into a gaseous form that collects in the headspace. The inert gas continues 
to carry the NO from the headspace, through a glass chemical trap containing 
10 - 15 ml of 1 M NaOH, then to the nitric oxide analyser (NOA) where it enters 
the reaction chamber and is eventually detected and quantified. The principle of 
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the NOA is dependent on the rapid reaction between NO and ozone (O3) which 
produces nitrogen dioxide in an excited state (NO2*) (Equation 20) 
396.   
NO + O3  NO2* + O2                                                                                     (20) 
As the excited electron of the NO2* returns to the ground state it releases a 
photon (h) in the form of light in the red and infrared part of the spectrum (640 
- 3000 nm) 397 (Equation 21).  
NO2*  NO2 + h                                                                                             (21) 
A photomultiplier tube (PMT) then amplifies the sensed light generating an 
electrical signal that can be recorded and quantified by a computer and 
appropriate software. Examples of the traces obtained can be seen in Figure 
2.8.  The complete set up can be seen in Figure 2.9. 
 
 
Figure 2.8: A signal tracing recorded by the data analysing software. Each peak corresponds to 
a sample injection into the purge vessel. The size of the peak (area under the curve) is 
proportional to the quantity of NO detected. NO – nitric oxide.  
 
 
















Figure 2.9: Chemiluminescence apparatus set up. The sample is injected into the purge vessel 
containing the redox agent. The NO-containing species is reduced and NO is released. The 
inert gas carries the NO from the purge vessel to the NOA. NO reacts with ozone releasing a 
photon that is detected by the analyser as a signal. The signal is translated and recorded by the 
data recording software. NO - nitric oxide, NOA - nitric oxide analyser, PC - personal computer.  
 
When measuring SNOs the purge vessel is filled with acidified tri-iodide (I3
-), a 
redox chemical that is able to reduce a host of NO-containing species 29,398. Tri-
iodide exists in the acidified solution as I3
- but also as free iodine (I-) and iodide 
(I2) (Equation 22) and readily reduces SNOs, forming a disulphide (RSSR) 
intermediate and NO+ (Equation 23), the later forming NO in a sequence of 
reactions as seen in Equations 18 and 19.    
I3
−  I- + I2                                                                                                       (22) 
I3
− + 2RS-NO  3I− + RSSR + 2NO+        (23) 
However, as the free iodine from the tri-iodide reacts with nitrite reducing it and 
releasing free NO, it is necessary to treat the sample in a way as to render nitrite 
undetectable via chemiluminescence. Depleting the sample of nitrite is 
accomplished by the addition of acidified sulfanilamide which reacts with the nitrite 
to form a diazonium cation that is stable in tri-iodide and does not generate a signal 
399
. It has been proposed that treatment with acidified sulfanilamide also degrades 
SNOs 
400
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SNO-Hb (87.6%), SNO-HAS (90.8%), GSNO (96.8%) and Cys-SNO (99.5%), when 
treated with acidified sulfanilamide 
378
. 
However, using CLD to measure circulating levels of SNO’s in this study does 
present a unique set of difficulties. For instance the standards used to establish 
standard curve were based on nitrite and not artificial SNO’s.  Furthermore, it 
has been suggested that chemicals used in preparing the samples for SNO 
analysis do not completely remove nitrite from the sample and may cause the 
decomposition of SNOs, thus, hindering accurate quantification 401.  Besides, if 
nitrite were to be successfully depleted from the sample, this alone would affect 
the levels of SNOs, as the two exist in equilibrium 401. Moreover, SNOs posses 
variable half lives with some only lasting for seconds, which makes measuring 
them in samples stored for even a short period of time especially challenging 
402. Other factors affecting this assay are the nature and conformation of the 
SNO moiety being measured. Thus, although SNO’s have a high degree of 
stability following acidification (as stated above), a change in their confirmation 
may affect the assay. 
Although CLD is highly sensitive there is a wide disparity in baseline plasma 
nitrite levels reported in different studies 403-406. These discrepancies are likely 
to be a result of variations in sample preparation, assay techniques and 
possible contamination.  
Due to its rapid reaction with haemoglobin, nitrite has a short half-life (10 min) 
in the circulation 401. However, once the sample has been removed (without in 
vivo production) nitrite has a half-life of less than 2 min 405. Hence, it is 
imperative that the sample be processed immediately, and the plasma 
separated from the erythrocytes as swiftly as possible, either physically (via 
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centrifugation) or chemically (via the use of ferricyanide or carbon monoxide) 
407. Furthermore, nitrite is scavenged more rapidly by free haemoglobin, 
therefore the blood sample should be aspirated through a large bore cannula to 
avoid haemolysis. Regardless, a degree of degradation during the processing of 
the sample is unavoidable; however, doing this rapidly, using pre-chilled 
vacutainers, in addition to centrifugation at a low temperature (4°C) limits the 
degradation. 
Assay techniques can be improved by: (i) conducting the assay at temperatures 
of 40 °C by circulating warm water around the purge vessel reaction chamber, 
(ii) ensuring the vacuum in the purge vessel is intact and that there are no gas 
leaks in the system, (iii) maintaining the cell pressure at a constant level by 
adjusting the flow of the inert gas, (iv) minimising foaming by adding an 
antifoaming agent to the redox chemical when analysing proteinated samples, 
(v) changing the redox agent regularly and frequently after multiple injections, 
(vi) using a gas-tight Hamilton long (5 inch) bevelled needle syringe to inject the 
samples swiftly and directly into the centre of the bottom of the purge vessel, 
(vii) allowing sufficient time between consecutive injections.  
The pervasive nature of nitrite makes it a ubiquitous lab contaminant, present in 
tap water, tainting glassware and almost all clinical vacutainers 407,408. Although 
found only in trace amounts in tap water, nitrite’s low concentrations in plasma 
makes it imperative to use nitrite free water in all aspects of the analysis from 
preparing standards to cleaning the equipment. Nitrite’s levels are imperceptible 
in Millipore treated water 402 and so this should be used preferentially when 
conducting assays. Finally, heparin treated vacutainers should be used as they 
have been shown to have far less contamination than EDTA vacutainers 408.  
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2.7.2 Measuring plasma nitrite protocol  
Blood was sampled serially through an 18 gauge Venflon® cannula placed in a 
forearm vein. In some studies blood was taken from the arm receiving the 
infusion (ipsilateral arm) in addition to the contralateral arm. Five ml samples of 
blood were aspirated and immediately transferred to pre-chilled Lithium Heparin 
tubes (Vacuette®) and immediately spun at 4 °C for 5 min at 4700 RPM (Mikro 
220R centrifuge, Hettich GR®). The haemolysis-free supernatant plasma was 
removed and placed into two 1.5 ml pre-labelled Ependorff tubes. These 
samples were snap-frozen in liquid nitrogen and stored at -80 °C until the day of 
the analysis, when they were thawed and stored on ice. The levels of nitrite in 
whole plasma were analysed using the 280i Nitric Oxide Analyzer (Sievers 
Instruments, GE analytic instruments®). The Purge vessel was filled with 
sodium iodide dissolved in 99.8% glacial acetic acid to which a few drops of 
antifoaming agent were added. A stock solution of 100 mM sodium nitrite was 
used to prepare the standards which were used in generating the calibration 
curves. The series of standard dilutions was constructed by serial dilution of the 
stock solution giving concentrations of 100 nM, 0.5 μM, 1 μM, 5 μM, 10 μM, 50 
μM and 100 μM. HPLC nitrite free water was used in the preparation of the 
stock and standard solutions. Using an analytical syringe (Hamilton Bonaduz, 
GR, SW®), 50 μL samples of selected dilutions were injected, in duplicate, into 
the purge vessel directly onto the reducing agent. The NO generated was 
detected by the NOA and analysed by the software to generate the calibration 
curve. To maintain consistency, close attention was paid to the volume of 
reducing agent, the maintenance of the cell pressure and the maintenance of 
the gas pressure. Once a satisfactory calibration curve had been generated, 50 
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μL of the plasma samples were injected, in duplicate, into the purge vessel. The 
reducing agent in the purge vessel was changed after each duplicate. The 
concentrations of nitrite were derived from the calibration curve. For most 
studies whole plasma was used, with antifoam added to the chamber to reduce 
frothing. In the intra-venous nitrite study, plasma was deproteinated using 3K 
Microcon filters (Merck Millipore®).  
2.7.3 Measuring plasma s-nitrosothiols protocol  
Using an 18 gauge needle, blood samples were collected from the contralateral 
arm at baseline and from the infused arm at the end of the study. Blood (~5 ml) 
samples were aspirated and treated in an identical manner as those described 
above for plasma nitrite. On the day of the analysis the samples were thawed 
and placed on ice. At least three minutes prior to analysis part of the sample 
was treated with 5% acidified sulfanilamide (prepared daily by dissolving 5 g of 
sulfanilamide in 100 ml of 1 M HCl) in a ratio of 9:1 of sample to acidified 
sulfanilamide. Samples were analysed using the 280i Nitric Oxide Analyzer 
(Sievers Instruments, GE analytic instruments®) as per nitrite. The Purge vessel 
was filled with acidified tri-iodide (prepared daily by dissolving 2.0g of potassium 
iodide (KI) with 1.3 g of Iodine (I2) in 40 ml of distilled water (H2O) and 140 ml of 
99.8% glacial acetic acid) to which a few drops of antifoaming agent were 
added. The series of standard dilutions was constructed by serial dilution of the 
stock solution (100 mM sodium nitrite) giving concentrations of 5 nM, 10 nM, 25 
nM, 50 nM, 100 nM, and 250 nM. Using an analytic syringe (Hamilton Bonaduz, 
GR, SW®), samples were injected into the purging vessel in aliquots of 100 μL. 
Otherwise all remaining aspects of the analysis were conducted in a manner 
identical to the one described for plasma nitrite (Section 2.6.2).  
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2.8 Measurement of plasma cGMP 
2.8.1 Enzyme-immunoassay  
The Enzyme-Linked ImmunoSorbent Assay (ELISA) is an analytical technique 
that employs antibodies, antigens and enzymes in detecting and quantifying an 
analyte of interest (in this case cGMP) in a liquid or liquefied sample 408. The 
quantification of the analyte is achieved through a controlled sequence of 
biochemical reactions, culminating in the generation of a signal (usually a colour 
change) that can be measured then translated to express the concentration of 
analyte present in the sample. Maintaining the same basic principle but varying 
the sequential addition of the antibodies and antigens gives rise to slightly 
different assay methods; these are described as being either indirect, sandwich 
or competitive. 
The Amersham cGMP Enzymeimmunoassay Biotrak system (GE Healthcare ®) 
that was used to conduct the assessment of plasma cGMP levels relied on the 
competitive sequence.  
The first step of the competitive technique is known as the solid substrate or 
solid phase. In it a plate composed of multiple wells is pre-coated with an 
antigen that is then immobilised onto its surface (in this particular assay the 
solid substrate is a donkey anti-rabbit antigen).  The following step involves the 
addition of an antibody (in this assay a rabbit anti-cGMP antibody) with a 
particular affinity for the solid substrate. However, although part of the antibody 
does bind irreversibly to the solid substrate, an epitope with specificity for the 
analyte  (cGMP) remains free. When the analyte is added to the wells it binds to 
the available antibody epitope, forming a reversible complex. The next step of 
the sequence involves the addition of a pre-prepared enzyme linked form of the 
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analyte (in this assay it is a peroxidase conjugated cGMP). This construct 
(peroxidase conjugated cGMP) is in direct competition with the analyte (cGMP) 
giving the technique its name. In the penultimate step, the plate is washed so 
that only the ligands (cGMP or conjugated cGMP), which are bound by the 
antigen-antibody interactions to the solid phase (donkey anti-rabbit and rabbit 
anti-cGMP), remain fixed to the plate, while the unbound components are 
washed away. The proportion of cGMP vs. peroxidase-conjugated cGMP that 
remains bound depends on the concentration of the former. In the final step The 
plate is developed by adding the peroxidase enzymatic substrate 3,3’,5’5’-
tetramethylbenzidine (TMB), a chromogenic reporter which when cleaved leads 
to a detectable colour change that can be translated into a measurable signal. 
This is achieved via the transmission of a specific wavelength of light through 
the liquid and detecting the transmitted intensity by spectrophotometry. This 
signal is then used to indicate the quantity of the analyte (cGMP) in the sample 
(Fig 2.10). 
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Figure 2.7: Competitive cGMP enzyme-immunoassay: A) The solid phase where the antigen
 is fixed to the well . B) The antibody is added to the well. C) The antibody binds 
to the solid phase antigen, however an epitope remains free. D) The analyte (cGMP)  is added 
to the well and binds to the free epitope. E) The enzyme-linked analyte (peroxidase conjugated 
cGMP) is added to the well and competes with cGMP, however here cGMP remains un-
displaced. F) Conjugated-cGMP displaces cGMP. G and H) after washing the wells TMB is 
added: In (G) cGMP remains bound thus TMB remains inactivated. In (H) conjugated-cGMP is 
bound thus TMB binds to it and is activated as seen in (I). TMB - 3,3’,5’5’-tetramethylbenzidine.   
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2.8.2 Cyclic GMP assay protocol 
Blood samples (~4 ml each) were collected at appropriate time points, via an 18 
gauge cannula, placed in the anticubital fossa vein, of either the infused or 
contralateral arm and transferred to pre-chilled EDTA tubes (Vacuette®) and 
immediately spun at 4 °C for 5 min at 4700 RPM (Mikro 220R centrifuge, 
Hettich GR®). The haemolysis-free supernatant plasma was removed and 
placed into two 1.5 ml pre-labelled Ependorff tubes. These samples were snap-
frozen in liquid nitrogen and stored at -80 °C until the day of the analysis.  
The assessment was conducted using the Amersham cGMP 
Enzymeimmunoassay Biotrak system (GE Healthcare®). The reagents 
provided, in the assay kit, were allowed to equilibrate to room temperature prior 
to use. Diluted assay buffer was then reconstituted by adding, and thoroughly 
mixing, the contents of the provided concentrate to distilled water, bringing the 
total volume to 500 ml. The dilute wash buffer was reconstituted in an identical 
manner.  
Both the lyophilised cGMP antibody and the lyophilised cGMP conjugate were 
reconstituted by adding 11 ml of the diluted assay buffer to each of the 
individual bottles and gently mixing until completely dissolved. Care was taken 
to avoid excessive agitation and foaming.  
The stock standard of cGMP (10.24 pmol/ml) was reconstituted by adding 2.5 
ml of the diluted assay buffer to the acetylation standard bottle; the contents 
were carefully mixed until completely dissolved.  Eight further working standards 
were constructed by consecutive serial dilutions of the stock solution, with an 
equal volume of dilute assay buffer, giving concentrations of 5.12, 2.56, 1.28, 
0.64, 0.32, 0.16, 0.08 and 0.04 pmol/ml.  
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The plasma samples for analysis (or unknowns) were prepared by diluting the 
plasma with the assay buffer in a ratio of 10:1. A volume of 1 ml of each of the 
standards and each of the unknowns was transferred to an appropriately pre-
labelled polypropylene tube.  
At the completion of the above steps, the acetylation reagent was created by 
adding 2.5 ml of acetic anhydride to 5 ml of triethylamine in a glass vessel and 
mixing thoroughly.  The resulting reagent was added in aliquots (100 μL) to 
each of the polypropylene tubes containing 1ml volumes of the standards or 
unknowns; each tube was then immediately agitated using a vortex mixer.   
The pre-treated micro-plate was set up with sufficient wells to run non-specific 
binding (NSB) blanks, standards and unknowns. Excluding the wells designated 
as NSB, 100 μL of the diluted antiserum was added to all the wells. This was 
followed by adding 150 μL of the assay buffer to the NSB wells and 50 μL 
aliquots from all the acetylated standards and diluted plasma samples 
(unknowns) to the appropriate pre-designated wells. All samples were added in 
duplicate. On completion the micro-plate was covered, gently mixed and 
incubated at 3 - 5 oC for 2 hours.  
At the end of that time period the micro-plate was uncovered and aliquots of the 
dilute conjugate (100 μL) were added to each of the wells. The micro-plate was 
re-covered, gently mixed and allowed to incubate at 3 - 5 oC for 1 hour.  
At the completion of this time period the plate was carefully and thoroughly 
washed using the diluted wash buffer. The plate was blotted to ensure the 
removal of any residual wash buffer. Room temperature TMB hydrogen 
peroxide was immediately added to the wells in 200 μL aliquots. The micro-
plate was covered and agitated at room temperature on a shaker for 30 min.  
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The reaction was halted by adding 100 μL of 1 M sulphuric acid to all the wells. 
The end point value was determined using a spectrophotometric plate reader 
capable of measuring optical density at 450 nm. SoftMax Pro® microplate 
acquisition and analysis software was used to construct a standard curve of 
absorbance vs. log10 of the antigen concentration which was then used to 
quantify the concentration of cGMP in the (unknown) test samples.  
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Chapter 3 
Chapter 8 : Results – 1 
Intra-arterial sodium nitrite and GTN  
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3.1 Subjects  
A total of 43 healthy males were requited for the studies, of whom 16 took part 
in more than 1 study.  The demographic data for each study are shown in Table 
3.1.  




















































































Table 3.1: Demographic data. Data shown as mean±SD. NR – not recorded,  i.a. – intra-arterial,  
i.v. – intra-venous, ACZ – acetazolamide, RX – raloxefine,  O2 – Oxygen.  
Study 1: Fixed dose i.a. sodium nitrite 
Study 2: Dose responses to i.a: (a) sodium nitrite (b) GTN 
Study 3: Effect of oral acetazolamide and raloxifene on the dose response to i.a. sodium nitrite 
Study 4: Effect of a co-infusion of i.a. acetazolamide and sodium nitrite  
Study 5: Effect of normoxia, hypoxia, and hyperoxia on the dose response to i.a. sodium nitrite 
Study 6: Fixed dose i.v. sodium nitrite  
3.2 Statistical Analysis 
The data from the studies was analysed using the Graph Pad Prism Software. 
All data are expressed as mean (95% confidence intervals) unless otherwise 
stated. Data were compared by repeated-measures ANOVA (2-tailed) with 
Dunnett’s post test for comparison with baseline and Bonferroni post test for 
comparison with the control group. P values <0.05 were considered statistically 
significant, unless Bonferroni corrections for multiple comparisons were 
required, as stated.  
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3.3 (Study 1) Intra-arterial sodium nitrite - fixed 
dose 
Sodium nitrite at a fixed dose of 8.7 μmol/ min was infused into the brachial 
artery, of 8 volunteers, for the duration of 60 min. Radial artery response was 
assessed at baseline, 5 min, 15 min, 30 min, 45 min and 60 min; FBF was 
assessed immediately following the end of each 2 min RA diameter acquisition.   
The intra-arterial infusion of sodium nitrite resulted in a marked dilatation of the 
RA at 5 min by 21.4 % (95% CI 15.3 to 27.6) compared to baseline saline, 
Figure 3.1. This was ~75% the value at 60 min, which was 28.3% (95% CI 22.1 
to 34.4). The data from one volunteer was excluded from the analysis as their 
radial artery dilatation to nitrite exceeded the mean + 2 SDs (of the entire group) 
at all time points. Furthermore, of particular note, the mean oxygen saturation of 
haemoglobin was 99% (range 97-100%), i.e. this dilatation did not occur under 
conditions of reduced oxygen tension found in small arterioles, or hypoxia (or 
ischemia) which have been considered essential for the effects of nitrite via its 
reduction to NO, but rather occurred under fully oxygenated conditions that are 
generally considered to inhibit nitrite bioactivation.   
As expected, sodium nitrite infusion increased FBF: this was by 2.1 ml/ min/ 100 
ml tissue (95% CI 0.7 to 3.5) at 5 min, see Figure 3.2, with no further significant 
increase over 60 min in the infused arm. However, FBF remained unchanged in 
the control forearm throughout the 60 min (Figure 3.2). There was an eight-fold 
elevation in systemic plasma nitrite concentration from 64±19 nmol/L at 
baseline to 528±128 nmol/L at 5 min and a 45-fold elevation to 2853±314 
nmol/L at 60 min (Figure 3.3). However, despite this rise in circulating nitrite 
there were no significant changes in heart rate nor in peripheral brachial blood 
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pressure (systolic, SBP, mean arterial, MAP, or diastolic, DBP) were detected 
during the 60 min infusion of sodium nitrite compared to baseline, i.e. time 0 min 
(Figure 3.4).  
Figure 3.1: Effect of 60 min intra-brachial infusion of sodium nitrite (8.7 μmol/ min) on change in 
artery (RA) diameter (%); Data shown as mean±SEM, n=7, ***P<0.001 compared to baseline, 
##
P<0.01 compared to 5 min.  
Figure 3.2: Effect of 60 min intra-brachial infusion of sodium nitrite (8.7 μmol/ min) on change in 
forearm blood flow (FBF). Data shown as mean±SEM, n=7,***P<0.001 compared to baseline.  
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Figure 3.3: Effect of 60 min intra-brachial infusion of sodium nitrite (8.7 μmol/ min) on systemic 
nitrite concentrations (blood sampled from contralateral arm). Data shown as mean±SEM, n=7, 





















































Figure 3.4: Effect of 60 min intra-brachial infusion of sodium nitrite (8.7 μmol/ min) on (A) 
peripheral brachial blood pressure (systolic, SBP, mean arterial, MAP, or diastolic, DBP). (B) 
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3.4 (Study 2) Intra-arterial sodium nitrite versus 
GTN - dose response   
In this study an intra-brachial infusion of sodium nitrite, was administered in a 
low (0.087 - 2.6 μmol/ min) and a high (8.7 - 87 μmol/ min) dose series 
spanning a dose response curve to 8 healthy volunteers. A different group of 7 
healthy volunteers were given an intra-brachial infusion of GTN in a single 
continuous series of dose steps (0.003 - 1 μg/ min). Radial artery responses 
were assessed at 5 - 7 min following each change in dose, while FBF changes 
were assessed at 20 - 22 min following each change with the change in the next 
dose occurring at 25 min. 
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3.4.1 Intra-arterial infusion of sodium nitrite - radial artery   
With nitrite the study comprised a low dose series (0.0, 0.087, 0.26, 0.87 and 
2.6 μmol/ min) with subjects returning to complete the higher dose series (8.7, 
26 and 87 μmol/ min), with each dose being infused for 25 min. The mean 
baseline radial artery measurements between the first and second visit were 
similar: 2.32±0.53 mm and 2.50±0.28 mm respectively (mean±SD). Figure 3.5A 
demonstrates a clear dose-response to nitrite in terms of radial artery diameter, 
with significant dilatation (compared to baseline) seen from doses of 0.87 μmol/ 
min, resulting in a dilatation of 11.2% (95% CI 2.6 to 19.8). The highest dose of 
87 μmol/ min resulted in a dilatation of 35.0% (95% CI 26.4 to 43.6).  
Radial artery measurements were made at 5 min following the initiation of each 
dose, while FBF was measured at 20 min. However, with nitrite (26 μmol/ min) 
radial artery measurements were also made at 20 min, and no differences were 
seen between this time point and 5 min.  
3.4.1.1 Intra-arterial sodium nitrite (in buffered saline) - radial artery   
Given that 0.9% saline has a pH of ~5.5, a separate series experiments were 
performed, in 4 volunteers, with sodium nitrite (0.087-26 μmol/ min) in saline, 
pH-balanced with sodium bicarbonate to pH 7.5±0.13 (mean±SD). Similar 
degrees of radial artery dilatation were found. (Figure 3.5B). 
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3.4.2 Intra-arterial GTN - radial artery    
The dose of GTN used (0.003 -1 μg/min = 1.3-5-4.4-3 μmol/min) resulted in 
significant radial artery dilatation (compared to baseline), with the dose of 0.01 
μg/ min, resulting in a dilatation of 13.6% (95% CI 2.9 to 22.4). The highest GTN 
dose (1.0 μg/ min) resulted in a dilatation of 33.3% (95% CI 22.5 to 44.1) see 
Figure 3.5C.  
Figure 3.5: Changes in radial artery (RA) diameter (%) with intra-brachial infusions of (A) 
sodium nitrite in saline (0.087-87 µmol/ min), (B) sodium nitrite in pH balanced saline (0.087-26 
μmol/ min) and     (C) GTN (0.003-1 μg/min). Data shown as mean±SEM, n=8 (nitrite in saline), 
n=4 (nitrite in pH balanced saline), and n=7 (GTN), *P<0.05 **P<0.01, ***P<0.001, compared to 
baseline, 
†††
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3.4.3 Intra-arterial sodium nitrite vs. GTN – FBF 
When assessing FBF both GTN and nitrite resulted in a significant increase. 
When compared to baseline the highest dose of nitrite (87 μmol/min) resulted in 
an increase of 6.21 ml/min/100ml (95% CI   4.82 to 7.59). The highest dose of 
GTN (1 μg/min) resulted in an increase of 4.31 ml/min/100ml (95% CI 2.58 to 
6.04). See figure 3.6   
 
Figure 3.6: Changes in radial artery forearm blood flow (FBF) with intra-brachial infusions of (A) 
sodium nitrite in saline (0.087-87 µmol/ min), (B) GTN (0.003-1 μg/min). Data shown as 
mean±SEM, n=8 (nitrite in saline), n=4 (nitrite in pH balanced saline), and n=7 (GTN),  
**P<0.01, ***P<0.001, compared to baseline, †††P<0.0001 across the dose range 
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3.4.4 Intra-arterial sodium nitrite vs. GTN - selectivity 
The selectivity of nitrite and GTN for vasodilating conduit arteries versus small 
resistance arterioles was compared by plotting the change in radial artery 
diameter, against the change in FBF at each dose step (see Figure 3.7). Nitrite 
resulted in a gradient of 4.9±0.6, with a strong correlation between conduit 
artery and resistance arteriole responses, r2 = 0.58, P<0.0001. With GTN the 
gradient was 5.7±1.3, but with a weaker association than nitrite, r2 = 0.33, 
P<0.0001. The Y-intercept was estimated at 6.4±1.8% for nitrite, compared to 
10.5±2.9% for GTN, (i.e. change in radial artery dilatation with no change in 
FBF), although the relationship is not linear at the lower doses for GTN, and the 
actual intercept is likely to be closer to ~6%. Overall, the large/conduit artery 
selectivity of GTN and nitrite were similar.  
Figure 3.7: Changes in radial artery (RA) diameter (%) versus change in forearm blood flow 
(FBF) with intra-brachial infusion nitrite (0.087-87 μmol/ min) and GTN (0.003-1 μg/min) at each 
dose step. Data shown as mean±SEM, n=8 (nitrite) and n=7 (GTN).  
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3.4.5 Intra-arterial infusion of sodium nitrite - radial artery 
flow   
To determine whether conduit artery dilation was flow-mediated, an analysis of 
the Doppler US flow images was undertaken. This demonstrated that there was 
no change in radial artery peak flow (see Figure 3.8) despite the increase in 
flow in resistance vessels (FBF). 
 
Figure 3.8: Effect of high dose sodium nitrite intrabrachial infusion of sodium nitrite (8.7, 26, 87 
μmol / min) on RA flow. Data shown as mean±SEM, n=7. RA – Radial artery. 
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3.4.6 Intra-arterial sodium nitrite vs. GTN - haemodynamics 
No changes in peripheral SBP, DBP or MAP or HR were found following the 
highest GTN dose, or with nitrite up to the penultimate dose of 26 μmol/min (see 
Figure 3.9). However, at the highest dose of nitrite (87 μmol/min) for 5 min, BP 
decreased by ~5.5/14 (11) mmHg (SBP/DBP (MAP) respectively) and HR 
increased by 19 bpm (P<0.001). The MAP transiently fell by more than the pre-
specified threshold of 15 mmHg in only one subject, at the end of the infusion of 
the highest dose. 
 
Figure 3.9: Effect of intra-brachial sodium nitrite across a high dose series (8.7, 26 and 87 μmol/ 
min, each dose infused for 25 min, 25 min and 5 min, respectively) on (A) peripheral Systolic 
Blood Pressure (pSBP) measured before and immediately after cessation of the infusion, and 
(B) peripheral Systolic Blood Pressure (pSBP) measured during the infusion of sodium nitrite at 
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3.4.7 Intra-arterial sodium nitrite vs. GTN - venoselectivity 
During i.a infusion of the low dose series of nitrite (n=3) and i.a. infusion of GTN 
(n=3), venous capacitance was measured by keeping the arm cuffs inflated at 
40 mmHg and assessing changes in forearm volume at 2.5 minutes 5. Low dose 
nitrite increased forearm venous capacitance in the infused arm compared to 
the control arm at a dose of 2.6 μmol/min (see Figure 3.10). Nitrite resulted in 
conduit artery dilatation with lower doses (0.26 and 0.87 μmol/min). Forearm 
venous capacitance was also increased by GTN compared to baseline in the 
infused arm, but not on comparison with the control arm. Therefore venodilatory 
effects were observed for nitrite and GTN. Since these studies were performed 




Figure 3.10: Venous Capacitance: change in forearm volume with intra-brachial infusions of (A) 
sodium nitrite (0.087-2.6 μmol/ min) and (B) GTN (0.003-1 μg/min). Data shown as mean±SEM, 
n=3 in both groups; 
††
P<0.01 compared to control on 2-way ANOVA, *P<0.05 on Bonferroni 




P<0.01compared to baseline (1-way ANOVA).  
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3.4.8 Intra-arterial sodium nitrite and systemic 
methaemoglobin 
Systemic methaemoglobin levels increased from 1.3±0.1% to 3.5±0.2% with the 
highest dose of nitrite, associated with a concomitant decrease in haemoglobin 
oxygen saturations from 98.5±0.1% to 97.0±0.4% (see Figure 3.11). 




Figure 3.1: Effect of intra-brachial infusion of sodium nitrite (dose response 0.087-87 μmol/ min) 
on percentage methaemoglobin (MetHb (%)) in infused and control arm (left Y-axis) and 
percentage haemoglobin oxygen saturations (SaO2 (%)) in control arm (right Y-axis). Data 
shown as mean±SEM, n=8, *P<0.05, ***P<0.001, compared to baseline.   
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3.4.9 Plasma nitrite, cyclic GMP and s-nitrosothiols levels   
Plasma nitrite concentrations, following sodium nitrite infusion, in the infused 
and contralateral arms are shown in Figure 3.12A. Nitrite levels at baseline 
were comparable in the infused and control arm (0.046±0.015 µmol/L and 
0.054±0.022 µmol/L respectively). It should be noted that the concentrations 
depicted in the graph are absolute concentrations that were not corrected for 
changes in flow.  
To determine changes in local cGMP production, we multiplied cGMP plasma 
concentrations by FBF; units are expressed in picomoles produced per min per 
100 ml of tissue.6  As shown in Figure 3.12B, nitrite infusion (2.6, 26, 87 
μmol/min) increased cGMP production in a dose-dependent manner, by 1.1 
pmol/min/100 ml tissue (95% CI 0.5 to 1.8), 2.2 pmol/min/100 ml tissue (95% CI 
1.2 to 3.2), and 4.7 pmol/min/100 ml tissue (95% CI 3.3 to 6.2), respectively. 
However, no systemic changes in cGMP production (in the contralateral arm) 
were detected. One set of cGMP data pertaining to nitrite (2.6 μmol/min) in the 
infused arm, was excluded from the analysis as the cGMP levels exceeded the 
mean + 2 SDs (of the entire set).   
Plasma SNOs in the infused arm were below the level of detection at baseline, 
and at most of the doses of nitrite infused. However, with nitrite infusion at the 
highest dose (87 μmol/min), plasma SNOs production was 348±130 
pmol/min/100 ml of tissue.  
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Figure 3.12: Effect of intra-brachial infusions of sodium nitrite on (A) plasma nitrite concentration 
in infused and contralateral arms (n=8), and  (B) plasma cGMP production: (i) nitrite (0, 0.26 
and 2.6 μmol/ min), cGMP in intervention arm (n=6), (ii) nitrite (0, 26 μmol/min), cGMP in 
intervention arm (n=7), (iii) nitrite (87 μmol/min), cGMP in intervention and control arms (n=5). 




P<0.001 compared to control arm,  **P<0.01, 
***P<0.001 compared to nitrite (0 μmol/ min), 
‡‡
P<0.01 for dose response, 
†††
P<0.0001 
compared to control arm on ANOVA.  
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Chapter 4 
Chapter 9 : Results – 2 
Intra-arterial sodium nitrite with 
acetazolamide or raloxifene 
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4.1 (Study 3) Intra-arterial sodium nitrite with oral 
acetazolamide and raloxifene  
As described previously (in chapter 1) both carbonic anhydrase 7 (through nitrite 
anhydartion) and aldehyde oxidase 8 (through nitrite reduction) have been 
shown to potentiate the release of NO from nitrite. Carbonic anhydrase is found 
on erythrocytes 62 while AO is located in the vascular tree 70,224. To investigate 
the role played by each enzyme, in nitrite’s effects on human conduit vessels, 
the CA inhibitor acetazolamide and the AO inhibitor raloxifene were used in an 
attempt to modify the effects of intra-arterial nitrite on the RA. In addition, AO 
has also been implicated in the generation of ROS 402, thus the use of raloxifene 
would also allow for the determination of the net effect of inhibition of AO-
dependent nitrite reduction versus inhibition of AO-derived ROS, with 
concomitant increase in NO bioavailability.  
The sample size calculation conducted was based on quantitative data set 
estimating a standard deviation in the population of 7% in RA diameter 
dilatation and a 25% mean difference between the control group and the 
intervention groups to be relevant to be detected with a confidence interval of 
5% and a confidence level of 95% the sample size required was calculated to 
be ~ 8.  
The infusion of nitrite alone dilated the RA by ~ 25%. Using the infusion of nitrite 
alone  as the control and comparing that with the intervention (nitrite + 
acetazolamide or nitrite + raloxifene) and aiming to detect a variation in RA 
dilatation of 50% between the two groups results in an actual target difference 
of 25% / 2 =  12.5% in actual RA dilatation. Allowing for a standard deviation of 
7%, thus, the standardised difference would calculated as follows:  
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Standardised difference = target difference / standard deviation  
Standardised difference = 12.5 / 7  
Standardised difference = 1.78  
Using the appropriate sample size formula: Sample size = (2 / standardised 
difference 2) x Cp,power, n = (2 / 1.78
2) x 13.0, n = (2/3.2) x 13.0 , n = 8.12 
Allowing for a Latin square design and the multiple comparisons between the 
control group and two intervention groups the total calculated sample size was 
8 x 2 = 16. We attempted to recruit 18 volunteers however regretfully due to 
multiple dropouts only Fourteen healthy male volunteers attended on 3 
occasions to receive an oral dose of either: (i) acetazolamide (500 mg), (ii) 
raloxifene (120 mg), or (iii) placebo (standard lactose tablet), according to a 
single-blind, randomized, balanced cross-over (Latin-square) design, 2 h before 
brachial artery cannulation and commencement of intra-arterial sodium nitrite 
infusion. 
Oral administration of acetazolamide (500 mg) or raloxifene (120 mg) had no 
effect on baseline radial artery diameter: 2.689±0.255 mm with placebo, 
2.711±0.265 mm with acetazolamide and 2.737±0.257 mm with raloxifene 
(mean±SD). However, acetazolamide enhanced radial artery dilatation to 
sodium nitrite: reaching the required significance level (P=0.0248), as did 
Raloxifene (P=0.0006), see Figure 4.1.  
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Figure 4.1: Effect of the administration of (A) oral acetazolamide and (B) oral raloxifene on the 
change in conduit artery (radial) diameter (%) during an intrabrachial infusion of sodium nitrite 





compared to placebo.   
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4.2 (Study 4) Intra-arterial sodium nitrite with 
intra-arterial acetazolamide  
In an attempt to negate any systemic effects of acetazolamide (when taken 
orally) this study was conducted to isolate local effects by administering a co-
infusion of i.a. acetazolamide and sodium nitrite and measuring their effects on 
RA diameter and FBF. Eight healthy volunteers attended on 3 occasions. On 
the first two visits nitrite was infused alone at a fixed dose (2.6 μmol/ min), or 
co-administered with acetazolamide (0.1 – 3.0 mg/ ml), each dose for 7 min with 
measurements taken at the end of this period, in a single-blind, randomized, 
balanced design. On the 3rd visit i.a acetazolamide was infused alone (0.1 – 3.0 
mg/ ml).  
Co-infusion of acetazolamide (0.1 - 3.0 mg/ min) with sodium nitrite (2.6 μmol/ 
min) enhanced nitrite-induced radial artery dilatation compared to sodium nitrite 
alone (P<0.0001), see Figure 4.2A. However, FBF was not increased, rather, 
there was a trend for acetazolamide to blunt the vasodilatory effect of nitrite in 
the resistance arterioles (P=0.10), see Figure 4.2B. The infusion of 
acetazolamide alone had no effect on FBF; however, it paradoxically diminished 
(rather than increasing) radial artery diameter (P=0.03).  
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Figure 4.2: Effect of the intra-brachial administration of acetazolamide (0.1-3 mg/min), nitrite 
(2.6 μmol/ min) or both in combination on (A) the change in radial artery (RA) diameter and (B) 
the change in forearm blood flow (FBF). Data shown as mean±SEM, n=8, 
†††
P<0.0001, *P<0.05 





P<0.05 compared to baseline (1-way ANOVA, with Dunnett’s 
post-testing respectively).  
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4.2.1 Intra-arterial sodium nitrite - onset of action  
In this cohort of volunteers, acquisition of continuous US imaging of the radial 
artery, following the commencement of nitrite (2.6 µmol/ ml) was undertaken to 
asses nitrite’s rate of action. This revealed a rapid onset of dilatation (half life 





Figure 4.3: Change in RA diameter over the first 8 minutes of intrabrachial nitrite infusion (2.6 
μmol/ min). Data represents mean, recordings every 3 seconds, n=8.  
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Chapter 5 
Chapter 10 : Results – 3 
Intra-arterial sodium nitrite under 
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5.1 (Study 5) Intra-arterial sodium nitrite under 
normoxia, hypoxia and hyperoxia 
The Effect of normoxia, hypoxia, and hyperoxia on the dose response to i.a. 
sodium nitrite (0.087 – 26 µmol/ ml) in the radial artery was investigated in 8 
volunteers. Healthy male participants attended on 3 occasions where sodium 
nitrite was infused while inhaling (i) room air (21%O2), (ii) 12% O2, or (iii) 100% 
O2 in a single-blind, randomized, Latin-square balanced design. Radial artery 
responses were assessed at 5-7 min following each change in dose.  
As shown in Figure 5.1, hypoxia and hyperoxia both inhibited radial artery 
dilatation to nitrite (to a similar extent) compared to normoxia (P<0.0001 and 
P=0.0006, respectively). Sodium nitrite (8.7 µmol/ ml) dilated the radial artery by 
only 19.0±2.6% under hypoxia, compared to 29.1±4.1% under normoxia 
(absolute difference of 10.1%, 95% CI of difference 1.90 to 18.3). Importantly, 
baseline radial artery diameter was almost identical under hypoxia, normoxia 
and hyperoxia: 2.743±0.221 mm, 2.841±0.292 mm, 2.728±0.218 mm (mean 
±SD) respectively. In addition, there were no differences in BP or HR between 
the conditions from baseline to the end of the study (see Figure 5.2). Therefore, 
there was no physiological evidence of increased sympathetic activity, or any 
effect on conduit artery tone as a result of hypoxia per se. 
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Figure 1.1: Effect of systemic hypoxia, normoxia and hyperoxia on the change in radial artery 
(RA) diameter during an intra-brachial infusion of sodium nitrite (0.087-26 μmol/ min); n=8, 
**P<0.01 compared to hypoxia, 
†††
P<0.001 compared to hypoxia and hyperoxia.  
Figure 5.2: Effect of hypoxia v normoxia v hyperoxia during an intra-brachial infusion of sodium 
nitrite (0.087-26 µmol/ ml) on peripheral brachial blood pressure, BP, ((A) systolic, SBP, (B) 
diastolic, DBP, (C) mean arterial, MABP and (D) heart rate (HR). Data shown as mean±SEM, 
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In contrast to radial artery responses, but in keeping with previous studies,402,409 
the change in FBF in the intervention arm (assessed in the last 3 subjects) was 
2.2 ml/ min/ 100 ml greater under hypoxia than normoxia (95% CI 0.6 to 3.8) at 
the highest dose of nitrite (26 µmol/ ml) as shown in Figure 5.3. There was no 
significant difference in baseline FBF between hypoxia and normoxia, again 
showing no physiological evidence of increased sympathetic activity. The 
overall haemoglobin O2 saturation recorded during the hypoxia study was 
91.6±3.4%, compared to 98.4±0.8% and 100±0.0% in normoxia and hyperoxia, 
respectively (mean ±SD). As shown in Figure 5.4, analysis of the ABGs taken at 
the end of the study, reveal that the pCO2 was greater during normoxia (5.1±0.2 
kPa) than during hypoxia (4.5±0.3 kPa), P=0.015 with no difference in 
bicarbonate; pH was lower during normoxia (pH 7.396±0.006) compared to pH 
7.44±0.01 during hypoxia (P<0.05). Besides pO2, there were no differences in 
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Figure 5.3: Effect of systemic hypoxia and normoxia on the change in forearm blood flow during 
an intra-brachial infusion of sodium nitrite (0.087-26 µmol/ ml). Data shown as mean±SEM, n=3, 
**P<0.01 compared to normoxia.  
Figure 5.4: Effect of hypoxia v normoxia v hyperoxia on arterial blood gas parameters: (A) O2 
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Chapter 6 
Chapter 11 : Results – 4 
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6.1 (Study 6) Intra-venous sodium nitrite  
To investigate the systemic effects of sodium nitrite, an intra-venous infusion 
was administered at a fix dose (8.7 μmol/min) for the duration of 60 min in 9 
healthy male volunteers. Sodium nitrite was also effective systemically dilating 
the RA in the contralateral forearm by 10.7% (95% CI 6.8 to 14.7) at 45 min, 
see Figure 6.1A. 
The profile of the increase in systemic plasma nitrite concentration with 
intravenous nitrite was similar to the intra-arterial study (see figure 6.1B), 
although the baseline concentration was higher (0.379±0.065 μmol/L, compared 
to 0.064±0.019 μmol/L previously) a consequence of the different method 
(deproteination of plasma using filters versus whole plasma, respectively) the 
former being typically associated with higher levels in this range, which may be 
due to contamination of the filters with nitrite.  
As with the intra-arterial administration of sodium nitrite, intravenous sodium 
nitrite did not result in any significant changes in peripheral brachial BP (SBP, 
MAP, or DBP) during the 60 min infusion of sodium nitrite compared to 
baseline, time 0 min (see Figure 6.2A). Assessments of central haemodynamics 
were performed from the third subject onwards (n=7). Sodium nitrite produced 
large reductions in central SBP of 11.6 mmHg, (95% CI of difference 2.4 to 
20.7, see Figure 6.2B and peripheral augmentation index (AIx) by 11.9% (95% 
CI of difference 0.5 to 23.2, see Figure 6.2C. Nitrite also reduced central pulse 
pressure (cPP) by 11 mmHg from 28 (19, 38) to 17 (15, 31) (median, IQR) 
(P=0.042) and pulse wave velocity (brachial-femoral) by 1.23 m/s (95% CI 0.28 
to 2.19).  
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Figure 6.1: Effect of intravenous sodium nitrite (8.7 µmol/ ml over 60 min) on, (A) change in 
radial artery (RA) diameter (%) in the contralateral arm, (B) on systemic plasma nitrite 
concentrations. Data shown as mean±SEM, n=9, *P<0.05, **P<0.01 compared to baseline, 
†††
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Figure 6.2: Effect of intravenous sodium nitrite (8.7 µmol/ ml over 60 min) on (A) peripheral 
brachial blood pressure (BP) measurements (systolic, SBP, mean arterial, MAP, or diastolic, 
DBP), (B) central Systolic Blood Pressure (cSBP), and (D) peripheral augmentation index (pAIx) 
performed before and after the 60 min infusion of sodium nitrite. Data shown as mean±SEM, 
n=9 for A, n=7 for B&C, *P<0.05.  
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Chapter 7 
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7.1 Discoveries 
These studies have led to several discoveries:  
(i) Sodium nitrite at supra-physiological concentrations, administered via the 
intra-arterial route causes rapid and marked dilatation of the radial artery under 
normal oxygenated conditions.  
(ii) Nitrite’s actions were highly selective for conduit arteries, to a similar degree 
as GTN, one of the most selective large/conduit artery dilators identified to date.  
(iii) Nitrite resulted in enhanced cGMP production in a dose-dependent manner, 
suggesting NO-mediated vasodilatory effects.  
(iv) The effects of nitrite in the radial artery were enhanced by (a) 
acetazolamide, suggesting a role for carbonic anhydrase, and (b) raloxifene, 
possibly via inhibition of AO-mediated ROS generation.  
(v) Nitrite-induced radial artery dilatation was maximal under conditions of 
normoxia, being inhibited by hypoxia and hyperoxia,  
(vi) Intravenous sodium nitrite was also an effective systemic conduit artery 
dilator, causing significant dilatation of the contralateral radial artery (~11%), 
associated with a lowering of cSBP (by ~12 mmHg) and cPP (by ~11 mmHg), at 
a dose that was not associated with any change in peripheral BP.  
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7.2 Local activity of sodium nitrite 
The rapid effect of nitrite in the radial artery – within minutes, suggests a direct 
local effect. This was not related to a flow-mediated dilatory mechanism, as no 
change in conduit artery flow was detected. In addition, the variable selectivity 
of different vasodilators for conduit versus resistance vessels indicates that 
conduit artery dilatation occurs independently of forearm blood flow 409.  For 
example, alpha blockers and calcium channel blockers are effective at 
increasing FBF but have minimal effect on conduit artery diameter 410. 
Furthermore, intravenous nitrite (8.7 μmol/min) did not increase FBF 
systemically, but resulted in radial artery dilatation of ~11%. Also, intra-arterial 
co-infusion of acetazolamide enhanced nitrite-induced radial artery dilatation, 
despite causing a borderline reduction in FBF (P=0.10).  
Rather than being a key difference between organic and inorganic 
nitrates/nitrites as previously thought 411, nitrite displayed similar selectivity as 
GTN, one of the most selective large artery dilators known 412. Indeed, it 
appears that NO donors in general, such as organic nitrates and sodium 
nitroprusside show the greatest selectivity for muscular arteries over resistance 
arterioles 413. The principle mechanism underlying the vascular effects of 
organic nitrates is via activation of soluble guanylyl cyclase (sGC), increasing 
cGMP levels and activating cGMP-dependent protein kinases, and/or cyclic 
nucleotide-gated ion channels 25,63. These are the same targets for nitrite-
derived NO activity. Indeed, intra-arterial nitrite infusion increased local plasma 
cGMP production (regarded as the most sensitive marker of NO availability)33 in 
a dose-dependent manner, supporting nitrite-derived NO as the mechanism of 
dilatation. The precise mechanism for nitrite conversion to NO is not clear, as a 
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number of enzymes have been implicated in the catalysis of nitrite to NO in 
different tissue compartments. However, a key pathway considered to account 
for the effects of nitrite in small resistance vessels is nitrite reduction to NO via 
deoxHb 54.  In addition, it is possible that nitrite reduction to vasodilating NO is 
supported by fully oxygenated red cells which possess appreciable nitrite 
reductase activity in vitro; i.e., ~50% of the capacity of deoxygenated red cells 
to reduce nitrite (10 μM) to NO 55, reflecting the greater reductive potential of 
haem in the R (oxy) state tetramer 55, Thus, HbO2 saturations ~99% during 
normoxia could support nitrite reduction, although this is difficult to confirm or 
refute in this design of in vivo experiments.  
However, certain alternative enzymes that may enhance nitrite-derived NO 
production, or activity, are amenable to pharmacological manipulation in vivo. 
For example, carbonic anhydrase, an enzyme found in abundance in vessels 
and erythrocytes, has been demonstrated by Aamand et al, 29 to possess nitrite 
anhydrase activity (as the isolated enzyme and in tissue homogenates) 
increasing NO production, and enhancing nitrite-dependent dilatation in the rat 
aorta (at 1% O2). The CA inhibitor acetazolamide, prevents the hydration of CO2 
but not the anhydration of nitrite. It has been suggested that the two substrates 
bind to different groups in the active site and that acetazolamide may increase 
the affinity for nitrite, by occupying non-productive binding sites on the enzyme, 
thus enhancing its activity as a nitrite anhydrase 279. Notably, such activity 
appears to predominate around physiological pH, as the initial rates of NO 
production from nitrite via CA in the presence of acetazolamide were greater at 
pH 7.2 than pH 5.9, albeit under strict anaerobic conditions. Thus, administering 
acetazolamide (either systemically via the oral route, or locally via the intra-
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arterial route) significantly enhanced radial artery dilatation to nitrite, supporting 
this mechanism of enhanced NO production.   
Mechanisms which may enhance nitrite-derived NO activity include inhibition of 
ROS production. While XO is established as an important source of ROS, the 
activity of AO to generate ROS is ~25-fold greater than XO in human liver and 
rat hearts 414. Raloxifene, a potent inhibitor of AO 414, enhanced nitrite-induced 
dilatation of the human radial artery, and the rat aorta suggesting that AO-
mediated ROS production predominates over AO-mediated nitrite reduction in 
normoxia. On the other hand, conditions which increase ROS production such 
as hyperoxia 15, will diminish nitrite-derived NO activity. Indeed, hyperoxia 
inhibited nitrite-induced radial artery dilatation.   
Hypoxia has also been shown to amplify ROS production 414. It is therefore 
possible that this increased ROS production accounts for the attenuated dilatory 
effect of nitrite in the radial artery - to a similar degree as during hyperoxia, and 
this overrides the increased rate of nitrite reduction resulting from the greater 
proportion of deoxyHb encountered under hypoxic conditions in the conduit 
artery. By contrast, in the resistance vessels, hypoxia augmented nitrite-
increased FBF, as reported previously 414. This suggests less scavenging of NO 
in the arterioles, which may be, at least in part, a consequence of the 
erythrocyte-free zone 415 (see Figure 7.1).  In smaller vessels, a narrower 
erythrocyte-free zone results in a closer proximity of the erythrocyte to the 
vessel wall, minimizing the diffusion distance for NO and the duration in which it 
may be scavenged by ROS. In the larger radial artery, the wider erythrocyte-
free zone results in the opposite. Thus, in the resistance arteriole, the effects of 
enhanced reduction of nitrite via deoxyHb predominates, whereas in the conduit 
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vessel, scavenging by ROS prevails. A further mechanism for nitrite’s selective 
vascular effects in normoxia versus hypoxia, may involve the recently described 
endothelial Hbα, which is absent from larger arteries, but present in the 
myoendothelial junctions of small arteries, where it dampens responses to 
(eNOS-derived) NO 416. However, in hypoxia, it is possible that deoxyHbα 
supports further nitrite reduction to NO which is in the immediate vicinity of the 
vascular smooth muscle cells, enhancing vasodilatation of resistance arterioles.  
 
Figure 7.1: The larger gap between the erythrocyte and the vessel wall in the conduit artery 
(erythrocyte-free zone) increases the distance traversed by the NO messenger to reach the 
vessel wall which allows for greater scavenging by ROS. In the arteriole however, a smaller gap 
improves NO’s chance of reaching the vessel wall and exerting its effects. 
Furthermore, it is conceivable that nitrite exerts dual activity on the vasculature; 
where on one hand its effects are mediated through the classic NO-cGMP 
pathway and on the other, they are mediated via NO-independent signalling. 
The latter being effected either by nitrite directly 75,417 or through the formation 
of an intermediate that is not dependent on nitrite’s reduction to NO.  Thus, in 
conduit vessels nitrite’s NO-independent signalling pathway dominates whereas 
in resistance arterioles its actions are contingent on its conversion to NO.  
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S-nitrosothiols make an attractive candidate for such an intermediate. They are 
formed without the need for nitrite’s conversion to NO 115, being produced in 
both normoxic as well as hypoxic conditions (in various rodent tissues) 75 and 
have been shown to induce vasodilatation via cGMP-independent mechanisms 
63.  
In humans, nitrite-related SNO formation was observed following systemic 
intravenous infusions of sodium nitrite in healthy volunteers 63. And although in 
another study the infusion of nitrite intravenously did not result in SNO formation 
this is probably a result of the low amount of nitrite (30 μmol) administered as 
no dilatation in the brachial artery was observed 55. However in this same study 
the direct systemic infusion of GSNO resulted in dilatation of the brachial artery 
25.  The inability to record SNO levels at baseline or at most of the doses of 
nitrite infused in the studies reported in the results section, makes supporting or 
refuting this hypothesis problematic. Although SNO levels were easily 
recordable at the highest dose of 87 μmol it is difficult to ascertain if the rise in 
SNO levels was due to increased local intravascular production or due to 
production at other sites such as the liver due to systemic overspill.  
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7.3 Systemic activity of sodium nitrite  
Nitrite was effective systemically, with a modest dose (8.7 µmol/ ml, 0.6 mg/min) 
selectively dilating the radial artery by ~11% after 45 min with no effect on FBF.  
The delayed response represents the time for the systemic concentration of 
nitrite to accumulate, given an initial half-life of nitrite of ~20 min (with 
continuous infusion) 418. Consistent with this selective dilatation of conduit 
arteries, nitrite selectively lowered cSBP/cPP by ~12 mmHg/ ~11 mmHg 
respectively with no effect on peripheral BP. Nitrite also reduced peripheral AIx 
by 11.9±4.6%, which equates to a change in central AIx of ~10% 419. Selective 
dilatation of muscular conduit arteries is an accepted mechanism by which GTN 
selectively lowers central BP through a reduction in wave reflection 29. It is 
therefore likely that the effects of nitrite on central haemodynamics are 
mediated by a similar mechanism. The lack of effect of nitrite on peripheral BP 
is consistent with the findings from a recent study performed in 55 patients with 
peripheral arterial disease, which found no reduction in BP with sustained 
release sodium nitrite up to doses of 160 mg twice daily 420.  
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7.4 Clinical relevance of nitrite’s central effects 
Central pressures are different to brachial pressures due to (variable) pulse 
pressure amplification when moving from the aorta to the periphery 421. Central 
(aortic, carotid) pressures more closely reflect the load on the heart and brain 
and are at least as predictive of cardiovascular events and may be more 
predictive 11. In the CAFE study, the amlodipine±perindopril combination 
resulted in a lower central pulse pressures than the atenolol±thiazide 
combination, and was significantly associated with a composite outcome of total 
cardiovascular events 218. Central pulse pressures may therefore serve as a 
target in intervention strategies and the pharmacological use of a treatment, 
such as sodium nitrite, that selectively lowers cSBP/cPP/AIx, has the potential 
to reduce cardiovascular risk independently of any effect on peripheral blood 
pressure. A specific advantage of inorganic nitrate/nitrite (in contrast to organic 
nitrates) is that it does not appear to induce tolerance 11. 
Normalization of elevated aortic pulse wave velocity (aPWV, a marker of large 
elastic artery stiffness) was recently demonstrated in old mice given oral dietary 
nitrite supplementation for 3-weeks 134. While acutely, dietary nitrate has 
recently been demonstrated to reduce aPWV by 0.3 m/s in healthy volunteers 
and by ~0.5 m/s in grade 1 hypertensives, this was in parallel with reductions in 
brachial systolic pressures of ~5 mmHg and ~12 mmHg respectively 422,423. Our 
current studies show an acute effect of nitrite, lowering bfPWV by ~1.2 m/s, 
independent of peripheral BP. 
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7.5 Limitations and Future studies 
All the studies reported involved healthy male volunteers. It remains to be 
determined whether these mechanisms would be similar in females and 
patients with vascular disease.  
Furthermore, other enzymatic pathways were not tested such as XOR, ALDH-2, 
CYP450, and interaction with PDE5. In addition, nitrite’s prospective capability 
of direct signalling (which has been attenuated using a COX inhibitor) was also 
not investigated.  
Conducting these studies would help further elucidate nitrite’s mechanism of 
action on conduit vessels and resistance arterioles and the possibility of a dual 
activity and other possible complex interactions.    
In a clinical setting these findings are exacting as they allow for the possibility of 
a multitude of new uses of inorganic nitrite. Glyceryl trinitrate is already 
extensively used to pre-dilate an occluded coronary vessel, prior to 
revascularization, in order to make a more accurate assessment of the vessel's 
calibre prior to the implantation of a suitably sized stent. If nitrite’s dilatory 
effects in the RA can be demonstrated in the epicardial coronary arteries (which 
are similar in calibre to the RA but differ in flow dynamics) when combined with 
nitrite’s mitigation of the deleterious effects of reperfusion, this would  allow it to 
be used in preference to GTN prior to coronary intervention.  
Furthermore, patients presenting with an acute coronary syndrome and on-
going chest pain who require prolonged treatment with intravenous GTN prior to 
percutaneous coronary intervention (which is in essence does cause a short 
period of interruption of blood flow and reperfusion) may benefit more from pre-
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treatment with intravenous nitrite. The argument here is that prolonged 
administration of GTN has been shown to exacerbate myocardial damage from 
reperfusion whereas inorganic nitrite has been found to be protective regardless 
of the duration of systemic delivery.  
The selective central haemodynamic effects of nitrite may have potential utility  
in medical emergencies where such an effect would be desirable such as an 
aortic dissection. Although GTN is already used as a drug of choice in this 
clinical setting, nitrite would provide a more superior option as tolerance does 
not develop with prolonged administration.  
These are few of the many new exciting potential clinical application of 
inorganic nitrite. One may argue that nitrite has fallen out of favour due to its 
unpredicted effects on the vascular system which on some occasions may lead 
to circulatory collapse. However, the studies that were conducted and came to 
this conclusion are out-dated and used preparations of nitrite that were far from 
ideal, described as “grains of nitrite” which could have contained widely varying 
quantities of the ion. It maybe that it is time for the circle to be complete and for 
inorganic nitrite / nitrate to transplant organic nitrite / nitrate in clinical.  
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7.6 Conclusion 
Over the last decade, the status of the nitrite anion has been transformed from 
an inactive metabolite of NO to a key source of the messenger. Although direct 
activity and the formation of other intermediates without the need for reduction 
have been demonstrated, the bulk of its actions are mediated through its 
conversion to NO. This conversion was thought to be contingent on conditions 
of hypoxia and/or ischemia thus making nitrite activity in the oxygenated arterial 
tree unlikely. However, contrary to expectation, inorganic nitrite selectively 
dilates conduit arteries under normal oxygenated conditions, to a similar degree 
as GTN, and selectively lowers central systolic/pulse pressure, with important 
therapeutic potential. These effects appear to be mediated via a carbonic 
anhydrase catalysed – cGMP-dependent mechanism in normoxia. The 
inhibition of conduit artery dilatation in hypoxia and hyperoxia, and the 
enhancement of dilatation by aldehyde oxidase inhibition, suggest an important 
role for ROS production in modulating these responses. These findings are a 
further step in the continuing evolution of the understanding of nitrite’s 
fundamental role in the cardiovascular system an understanding that is likely to 
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